Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 37758. Отображено 100.
12-01-2012 дата публикации

Recombinant polypeptide having pancreatic lipase activity and nucleic acid coding sequence thereof, and their production and use

Номер: US20120009324A1
Автор: Fang-Chueh Liu
Принадлежит: Livestock Res Inst Council of Agriculture

Disclosed herein is an isolated nucleic acid sequence encoding a recombinant polypeptide that has pancreatic lipase activity. Also disclosed herein are a recombinant vector and a recombinant host cell for producing the aforesaid recombinant polypeptide. The aforesaid recombinant polypeptide is adapted for preparation of an animal feed that is able to facilitate utilization of fats therein regarding pigs (especially postweaning pigs) and to enhance growth performance of the pigs.

Подробнее
Номер записи: 1
16-02-2012 дата публикации

Use of natural substances as feed additives for animals of the genus equidae

Номер: US20120040047A1
Автор: Birgit Elgaard, Marco Frehner, Petra Philipps, Riccardo Losa
Принадлежит: DSM IP ASSETS BV

The present invention relates to the use of natural active compounds selected from the group consisting of guajacol, turmeric, 3-methylphenol, eugenol, eucalyptol, L-menthol and thymol in the manufacture of a diet for animals of the genus equidae , preferably horses. More particular, this invention relates to the use of at least two, preferably at least three compounds as defined above for the improvement of the digestibility of the diet, an improved intestinal stability, a better feed intake and a better welfare and for stabilizing or modulating the gut micro flora of the animal.

Подробнее
Номер записи: 2
08-03-2012 дата публикации

Methods and Systems for Processing Sugar Mixtures and Resultant Compositions

Номер: US20120058526A1
Автор: AHARON Eyal, Robert Jansen
Принадлежит: HCL CleanTech Ltd

A method including: (a) selectively reacting a first sugar in a mixture which includes at least one second sugar to form a product mixture comprising a product of said first sugar; (b) separating said product of said first sugar from said product mixture; and (c) separating at least one of said at least one second sugar from said product mixture.

Подробнее
Номер записи: 3
29-03-2012 дата публикации

Method of Producing Dried Distiller's Grain with Solubles Agglomerated Particles

Номер: US20120076915A1
Автор: Russel J. Meier
Принадлежит: Individual

A method of producing Dried Distiller's Grain with Solubles (DDGS) agglomerated particles is disclosed. The method comprises the steps of separating a first product stream out of the whole stillage that is primarily solid material from a second product stream that is primarily liquid, agglomerating the first product stream using a mechanical compression machine such as an extruder, and exposing the agglomerated particles to microwave radiation of a sufficient energy for a sufficient time so that the resulting moisture of the agglomerated particles is between 3% and 40% by weight. The second product stream may be condensed and blended with the first product stream prior to, or concurrently with, the step in which the agglomerated particles are formed. Additionally, other additives, such as enzymes, may be added to the first product stream to enhance the final product's desirability as a nutritional source.

Подробнее
Номер записи: 4
29-03-2012 дата публикации

Coccidiosis controlling agent and feed containing the same

Номер: US20120077884A1
Автор: Chie Hikita, Kyo Nagashima, Masami Mochizuki
Принадлежит: Idemitsu Kosan Co Ltd

An object of the present invention is to provide: a coccidiosis controlling agent which is excellent in safety, is free of problems such as side-effects, does not cause effect reduction or the like due to the acquisition of resistance to a medicament, and exhibits a high preventive effect and a high treatment effect against coccidiosis; a feed for an animal containing the anticoccidial composition; and a method for raising an animal using the coccidiosis controlling agent and the feed. In order to solve the above-mentioned problem, provided is a coccidiosis controlling agent for an animal, containing heated cashew nut shell liquid and/or cardanol.

Подробнее
Номер записи: 5
19-04-2012 дата публикации

Birdseed formulations for attracting desirable birds from the midwestern region of the united states

Номер: US20120093969A1
Автор: Mario Olmos
Принадлежит: Central Garden and Pet Co

Birdseed blends are formulated to attract desirable birds that generally reside in the Midwestern Region and other similar regions of the United States. Such birdseed formulations may attract more birds than conventional black oil sunflower seeds alone or conventional birdseed mixes. In addition, such birdseed formulations also may generally attract more desirable birds than black oil sunflower seeds or conventional birdseed mixes, while attracting less undesirable birds.

Подробнее
Номер записи: 6
19-04-2012 дата публикации

Birdseed formulations for attracting desirable birds from the southern region of the united states

Номер: US20120093970A1
Автор: Mario Olmos
Принадлежит: Central Garden and Pet Co

Birdseed blends are formulated to attract desirable birds that generally reside in the Southern Region and other similar regions of the United States. Such birdseed formulations may attract more birds than conventional black oil sunflower seeds alone or conventional birdseed mixes. In addition, such birdseed formulations also may generally attract more desirable birds than black oil sunflower seeds or conventional birdseed mixes, while attracting less undesirable birds.

Подробнее
Номер записи: 7
10-05-2012 дата публикации

Polypeptides Having Phytase Activity and Polynucleotides Encoding Same

Номер: US20120114799A1
Автор: Carsten Sjoholm, Monica Takamiya Wik
Принадлежит: Novozymes AS

The invention relates to Citrobacter phytases derived from Citrobacter amalonaticus, Citrobacter gillenii , and related phytases. The phytases belong to the acid histidine phosphatase family, are acid-stable, and expectedly of a high specific activity. The invention also relates to the corresponding DNA, the recombinant and wild-type production of the phytases, as well as the use thereof, in particular in animal feed.

Подробнее
Номер записи: 8
24-05-2012 дата публикации

Novel microalgal food compositions

Номер: US20120128851A1
Автор: Dana Zdanis, Enrique Baliu, Geoffrey Brooks, Jeff Avila, John Piechocki, Leslie M. Norris, Scott Franklin, Stephen M. Decker, Walter Rakitsky
Принадлежит: Solazyme Inc

The invention provides novel microalgal food compositions comprising microalgal biomass that have been processed into flakes, powders and flours. The microalgal biomass of the invention is low in saturated fats, high in monounsaturated triglyceride oil and can be a good source of fiber. The invention also comprises microalgal biomass that is suitable as a vegetarian protein source and also as a good source of fiber. Novel methods of formulating food compositions with the microalgal biomass of the invention are also disclosed herein including beverages, baked goods, egg products, reduced fat foods and gluten-free foods. The provision of food compositions incorporating the microalgal biomass of the invention to ahuman have the further benefit of providing healthful ingredients while achieving levels of satiety sufficient to reduce further caloric intake. The invention also provides novel strains of microalgae that have been subject to non-transgenic methods of mutation sufficient to reduce the coloration of the biomass produced by the strains. Oil from the microalgal biomass can be extracted and is an edible oil that is heart-healthy. The novel microalgal biomass and oil therefrom can be manufactured from edible and inedible heterotrophic fermentation feedstocks, including corn starch, sugar cane, glycerol, and depolymerized cellulose that are purpose-grown or byproducts of existing agricultural processes from an extremely broad diversity of geographic regions.

Подробнее
Номер записи: 9
21-06-2012 дата публикации

Compositions and applications of carotenoids of improved absorption and bioavailability

Номер: US20120157547A1
Автор: José-Odon Torres-Quiroga, Ricardo Montoya-Olvera
Принадлежит: Industrial Organica de C V SA

Micro micellar form of carotenoids or xanthophylls, which show improved absorption and biovailability by living organisms, providing higher levels of carotenoids in the blood stream, and consequently are deposited at the target tissues at a faster rate, and more efficiently than crystalline carotenoids, which does not contain any crystal forms of carotenoids, and which are obtained as micro micelles after melting Lutein diacetate or Lutein dipropionate in their natural original lipid vegetable matrix, in the presence of lipids, phospholipids, fatty acids, emulsifiers and moisture, and are ingested in a dosage between 2 to 50 mg, to provide an absorption of the carotenoid solubilizate which is at least 20% above than that of crystalline carotenoids, and provides a macular pigment deposit which exceeds at least 10% of Macular Pigment Optical Density, than the deposition obtained by ingesting crystalline Lutein. Thus preventing tissue degeneration, UV light damage to skin and the retina, and in general to act as more effective and efficient antioxidants than when administered in crystalline form.

Подробнее
Номер записи: 10
09-08-2012 дата публикации

Synthetic phytase variants

Номер: US20120201923A1
Автор: Beata Stosik, Serwe Annegret, Stefan Haefner
Принадлежит: BASF SE

The invention relates to a synthetic phytase having an increased thermal stability and also to an isolated nucleic acid sequence encoding a synthetic phytase, and the use of the phytase in an animal feed for reducing the phosphtate content in manure, and also animal feed additives and animal feeds comprising the synthetic phytase.

Подробнее
Номер записи: 11
09-08-2012 дата публикации

Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use

Номер: US20120202759A1
Автор: Yuanlong Pan
Принадлежит: Nestec SA

Edible compositions useful for weight management in male animals are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites and are particularly useful for reducing or preventing the accumulation of body fat. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones. The compositions and methods are particularly useful for the reduction or prevention of body fat accumulation during periods of excess caloric intake, and preferably have a sparing effect on lean body mass.

Подробнее
Номер записи: 12
13-09-2012 дата публикации

Compositions And Methods for Nutritional Supplementation

Номер: US20120231087A1
Автор: Inge Bruheim, Mikko Griinari, Stig Rune Remoy
Принадлежит: Olympic Seafood AS

The present invention relates to nutritional supplement compositions comprising krill meal and lipid insoluble ingredients. The compositions can be used to provide supplementary nutrition to humans or animals. The present invention relates also formulations, such as tablets, which are easy to administer to animals. It is also shown that krill meal added to animal food at low levels will improve the palatability of the product.

Подробнее
Номер записи: 13
27-09-2012 дата публикации

Animal Feed

Номер: US20120244260A1
Автор: Helmut Deuerer
Принадлежит: Growth Finance Plus AG

The invention relates to an animal feed for dogs or cats based on animal tissue, water, and hydrocolloid as a thickener, wherein the animal feed includes a water content of at least 80% by weight, preferably at least 85% by weight. According to the invention, said feed is liquid at room temperature, has a fat content at least 1% by weight and less than 5% by weight, and is packed in a tubular bag, wherein the top side and the bottom side thereof are welded at a welding surface at a front end and back end of the tubular bag, and a designed fracture point for tearing open the bag is provided at the front end in the welding surface.

Подробнее
Номер записи: 14
11-10-2012 дата публикации

Compositions for Controlling Varroa Mites in Bees

Номер: US20120258646A1
Автор: Eyal Ben-Chanoch, Eyal Maori, Gal Yarden, Haim Kalev, Ilan Sela, Sharoni Shafir, Yael Garbian
Принадлежит: Beeologics Inc, Yissum Research Development Co of Hebrew University of Jerusalem

An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.

Подробнее
Номер записи: 15
08-11-2012 дата публикации

Rumen-Protected Lutein Product for Producing High-Lutein Dairy Products

Номер: US20120282367A1
Автор: DONG Chen, Ye Lao, Yongcai Liu, Zhiyong Duan
Принадлежит: Kemin Industries Inc

A rumen-protected carotenoid animal feed product is described that is free-flowing, resistant to ruminal degradation and effective at raising the carotenoid level in milk produced by the animal.

Подробнее
Номер записи: 16
29-11-2012 дата публикации

Method for lowering feed conversion rate

Номер: US20120301534A1
Автор: Tzong-Yueh Chen, Yi-Ling Huang
Принадлежит: National Cheng Kung University NCKU

The present invention provides a method for lowering the feed conversion rate in a vertebrate comprising inhibiting the function of secreted protein acidic and rich in cysteine (SPARC), wherein the feed conversion rate is defined as the mass of the feed eaten divided by the body mass gain.

Подробнее
Номер записи: 17
27-12-2012 дата публикации

Synergetic composition comprising flavouring substances and organic acids and use thereof

Номер: US20120329874A1
Автор: Andrea Piva, Maurizio Tedeschi
Принадлежит: Vetagro SpA

The present invention relates to a composition comprising a synergetic mixture of flavourings or flavouring substances and organic acids. Moreover, the present invention relates to the use of said composition as a preservative for animal foodstuffs and additives intended preferably for monogastric animals.

Подробнее
Номер записи: 18
03-01-2013 дата публикации

Ts-23 alpha-amylase variants with altered properties

Номер: US20130005029A1
Автор: Brain E. Jones, Casper Vroemen, Chris Leeflang, Claudine Chang, Clement Choy, James T. Kellis, Jr., Luis G. Cascao-Pereira, Marc Kolkman, Melodie Estabrook, Walter Weyler
Принадлежит: DANISCO US INC

Described are variants (mutants) of a parent alpha-amylase having alpha-amylase activity and exhibiting altered properties relative to the parent alpha-amylase, and methods of use, thereof.

Подробнее
Номер записи: 19
31-01-2013 дата публикации

Process For Preparing An Enzyme Containing Granule

Номер: US20130029010A1
Автор: Christian Pedersen, Erik Marcussen
Принадлежит: Novozymes AS

This invention relates to a process for manufacture of a dry enzyme containing mixer granulation granule comprising the step of adding a particulate component to the mixer granulation process, wherein the particulate component constitutes less than 75 parts of the finished granule and the particles of the particulate component have an mean size of more than 40 μm in its longest dimension. Also claimed is granules of the process, granules containing more than two particles of the particulate component and composition and methods of using the granules.

Подробнее
Номер записи: 20
14-03-2013 дата публикации

Spray Nozzle Application to Transfer Flavoring Liquid onto Dry Animal Food

Номер: US20130064949A1
Автор: Mark Todd Vanselous
Принадлежит: Individual

The application of a spray nozzle to delivery flavoring onto dry animal food for the purpose of making the dry food taste better so the animal is more likely to consume. Currently canned, bagged, gravy and leftover foods are used for this purpose, but are messy, smell and require mixing. The invention provides a better and more user friendly way for the animal owner, veterinarian or general to improve the flavor of dry animal food so the animal will consume with no mess, smell or mixing requirements.

Подробнее
Номер записи: 21
04-04-2013 дата публикации

Methods and compositions for improving the nutritional content of mushrooms and fungi

Номер: US20130084362A1
Автор: Michael Kalaras, Robert B. Beelman
Принадлежит: PENN STATE RESEARCH FOUNDATION

An improved filamentous fungi is disclosed that has an enhanced nutritional profile by utilizing pulsed ultraviolet irradiation. According to the invention, the vitamin D component of mushrooms and other filamentous fungi may be drastically increased with no deleterious affects on appearance with the use of pulsed UV radiation. Mushrooms so treated had up to 1800% DV in one serving of fresh mushrooms.

Подробнее
Номер записи: 22
04-04-2013 дата публикации

Method For Assay On The Effect Of Vascularization Inhibitor

Номер: US20130085152A1
Автор: Matsui Junji, Uenaka Toshimitsu, Yamamoto Yuji
Принадлежит: Eisai R&D Management Co., Ltd.

The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EOF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity. 180-. (canceled)821: The method according to claim , wherein the VEGF receptor kinase inhibitor is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide , a pharmacologically acceptable salt thereof , or a solvate of said compound or salt.831: The method according to claim , wherein the VEGF receptor kinase inhibitor is a methanesulfonic acid salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.841: The method according to claim , wherein the substance having EGF inhibitor activity is 4-(3-ethynylphenylamino)-6 ,7-bis(2-methoxyethoxy)-quinazoline , a pharmacologically acceptable salt thereof , or a solvate of said compound or salt. The present invention relates to a novel method for predicting the effect of angiogenesis inhibitors, such as substances having vascular endothelial growth factor (hereinafter, sometimes referred to as “VEGF”) inhibitory activity (hereinafter, sometimes referred to as “VEGF inhibitors”).The present invention also relates to a pharmaceutical composition comprising a combination of a VEGF receptor kinase inhibitor and a substance having EGF inhibitory activity (hereinafter, sometimes referred to as “EGF inhibitor”); a kit comprising the composition; and a method of treating cancers.Clinical trials have made it clear that angiogenesis inhibitors are useful as antitumor agents. For ...

Подробнее
Номер записи: 23
11-04-2013 дата публикации

Pharmaceutical Compositions and Administrations Thereof

Номер: US20130090354A1
Автор: Burton William Lawrence, Huang Chien-Jung, Negulescu Paul Adrian, Van Goor Fredrick F., Yu Haihui
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. 1. A method of treating a CFTR mediated disease in a human comprising administering Compound 1 to a patient possessing a human CFTR mutation selected from G178R , G551S , G970R , G1244E , S1255P , G1349D , S549N , S549R , S1251N , E193K , F1052V and G1069R.2. The method of claim 1 , wherein the human CFTR mutation is selected from G178R claim 1 , G551S claim 1 , G970R claim 1 , G1244E claim 1 , S1255P claim 1 , G1349D claim 1 , S549N claim 1 , S549R and S1251N.3. The method of claim 1 , wherein the human CFTR mutation is selected from E193K claim 1 , F1052V and G1069R.4. A method of treating a CFTR mediated disease in a human comprising administering Compound 1 to a patient possessing a human CFTR mutation selected from R117C claim 1 , D110H claim 1 , R347H claim 1 , R352Q claim 1 , E56K claim 1 , P67L claim 1 , L206W claim 1 , A455E claim 1 , D579G claim 1 , S1235R claim 1 , S945L claim 1 , R1070W claim 1 , F1074L claim 1 , D110E claim 1 , D1270N and D115214.5. A method of treating a CFTR mediated disease in a human comprising administering Compound 1 to a patient possessing a human CFTR mutation selected from G178R claim 1 , G551S claim 1 , G970R claim 1 , G1244E claim 1 , S1255P claim 1 , G1349D claim 1 , S549N claim 1 , S549R claim 1 , S1251N claim 1 , E193K claim 1 , F1052V and G1069R claim 1 , and a human CFTR mutation selected from ΔF508 claim 1 , R117H claim 1 , and G551D.6. The method of claim 5 , wherein Compound 1 is administered to a patient possessing a human CFTR mutation selected from G178R claim 5 , G551S claim 5 , G970R claim 5 , G1244E claim 5 , S1255P claim 5 , G1349D claim 5 , S549N claim 5 , S549R and S1251N claim 5 , and a human CFTR ...

Подробнее
Номер записи: 24
18-04-2013 дата публикации

Feed additive composition for ruminants and method of producing the same

Номер: US20130095206A1
Автор: Hidetsugu Nakazawa, Hiroyuki Sato, Sachiko Oka, Susumu Shibahara, Yuki Miyazawa, Yumi Goto
Принадлежит: Ajinomoto Co Inc

A food additive composition for ruminants of the dispersion type and a method of continuously producing the same. This food additive composition for ruminants, which contains 40% by weight or more but less than 65% by weight of a basic amino acid and has rumen bypass properties, is formulated into granules in an arbitrary shape which are scarcely classified when added to a silage or another feed. Thus, attempts have been made to develop a method of producing granules by which the milk yield of a lactation cow can be increased. Namely, it is intended to provide a food additive composition for ruminants which contains at least one protecting agent selected from among a hardened vegetable oil and a hardened animal oil having a melting point higher than 50° C. but lower than 90° C., 0.05 to 6% by weight of lecithin, water and 40% by weight or more but less than 65% by weight of a basic amino acid. It is also intended to provide a method of producing a food additive composition for ruminants characterized by comprising solidifying a molten mixture, which comprises at least one protecting agent selected from among a hardened vegetable oil and a hardened animal oil having a melting point higher than 50° C. but lower than 90° C., lecithin and a basic amino acid, by dipping in water.

Подробнее
Номер записи: 25
18-04-2013 дата публикации

Agglomerated particulate lignosulfonate

Номер: US20130095319A1
Автор: Kare Reknes
Принадлежит: Borregaard Industries Ltd

An agglomerated particulate lignosulfonate material may he made by introducing or forming lignosulfonate microparticles in a fluidized bed agglomerator, and introducing sufficient heated gas and lignosulfonate liquid in the agglomerator to convert the microparticles to lignosulfonate granules of enlarged size. The granules may have an average size of at least 0.1 mm, and may be used to make a dry-blended cement additive or oil well cement that may be dustless, easily poured and stored, and rapidly dissolved in water.

Подробнее
Номер записи: 26
16-05-2013 дата публикации

Antitumor Agent Using Compounds Having Kinase Inhibitory Effect in Combination

Номер: US20130123274A1
Автор: Funahashi Yasuhiro, Matsushima Tomohiro, Nakagawa Takayuki
Принадлежит: Eisai R&D Management Co., Ltd.

An antitumor agent for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound or pharmaceutically acceptable salt thereof represented by Formula (II) exhibits an excellent antitumor effect compared to cases where these are individually used, and exhibits antitumor effects against various cancer types: The present invention relates to an antitumor agent for combined use of compounds having a kinase inhibitory effect. Particularly, the present invention relates to an antitumor agent for combined use of a compound having a HGFR inhibitory effect and a compound having a multi-tyrosine kinase inhibitory effect.wherein Ris azetidinyl and the like, Rto Ris a hydrogen atom or a halogen atom, Ris Ccycloalkyl and the like, Ris a hydrogen atom and the like, and Ris a halogen atom and the like.The compound represented by Formula (I) has potent inhibitory effects against hepatocyte growth factor receptor (HGFR), and thus is useful as an antitumor agent, an angiogenesis inhibitor, and a tumor metastasis inhibitor (Patent Literature 1). HGFR is known to be overexpressed in a large number of tumor cells (Non Patent Literature 1) and involved in malignant alteration of tumors. Further, HGFR is also expressed in vascular endothelial cells, and is considered to cause the proliferation of tumors by promoting angiogenesis (Non Patent Literature 2).On the other hand, the compound represented by Formula (II) has anti-angiogenic actions (Patent Literature 2), inhibitory effects (Patent Literatures 3 to 6) against tyrosine kinases which are reported to be involved in malignant alteration of tumors (Non-Patent Literatures 3 to 5), and the like; and is known as a therapeutic agent for various tumors such as thyroid cancer, lung cancer, melanoma, endometrial cancer, gastric cancer and bladder cancer.In general, antitumor agents are often not effective for all of the patients when they were used individually. Thus, attempts have been ...

Подробнее
Номер записи: 27
23-05-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF

Номер: US20130131107A1
Автор: Alargova Rossitza Gueorguieva, Alcacio Tim Edward, Arekar Sneha G., Binch Hayley Marie, Botfield Martyn Curtis, Fanning Lev Tyler Dewey, Grootenhuis Peter Diederik Jan, Hurley Dennis James, Johnston Steven C., Kadiyala Irina Nikolaevna, Kaushik Ritu Rohit, Keshavarz-Shokri Ali, Krawiec Mariusz, Lee Elaine Chungmin, Luisi Brian, Medek Ales, Mudunuri Praveen, Numa Mehdi, Sheth Urvi Jagdishbhai, Silina Alina, Sullivan Mark Jeffrey, Van Goor Fredrick F., Verwijs Marinus Jacobus, Yang Xiaoqing, Young Christopher Ryan, Zaman Noreen Tasneem, Zhang Beili, Zhang Yuegang, Zlokarnik Gregor
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. 9. The pharmaceutical composition of claim 8 , wherein the Column A component is Compound 1 claim 8 , the Column B Component is Compound 2 claim 8 , and the third Component is any of the embodiments listed in Column C of Table I.10. The pharmaceutical composition of claim 8 , wherein the Column A component is Compound 1 claim 8 , the Column B Component is Compound 2 claim 8 , and the third Component is any of the embodiments listed in Column D of Table I.1128-. (canceled)29. A pharmaceutical composition comprising:a solid dispersion of Compound 1 or a pharmaceutically acceptable salt thereof; andCompound 3 or a pharmaceutically acceptable salt thereof.30. The pharmaceutical composition of claim 29 , wherein the solid dispersion of Compound 1 comprises about 80 wt % of substantially amorphous Compound 1 by weight of the dispersion claim 29 , about 19.5 wt % of HPMCAS by weight of the dispersion claim 29 , and about 0.5 wt % SLS by weight of the dispersion.31. The pharmaceutical composition of claim 30 , wherein the composition comprises about 34.1 wt % of the solid dispersion by weight of the composition; about 30.5 wt % of microcrystalline cellulose by weight of the composition; about 30.4 wt % of lactose by weight of the composition; about 3 wt % of sodium croscarmellose by weight of the composition; about 0.5 wt % of SLS by weight of the composition; about 0.5 wt % of colloidal silicon dioxide by weight of the composition; and about 1 wt % of magnesium stearate by weight of the composition.32. The pharmaceutical composition according to claim 31 , wherein the composition ...

Подробнее
Номер записи: 28
23-05-2013 дата публикации

Creatine oral supplementation using creatine hydrochloride salt

Номер: US20130131175A1
Автор: Donald W. Miller, Jonathan L. Vennerstrom, Mark C. Faulkner
Принадлежит: Vireo Systems Inc

The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

Подробнее
Номер записи: 29
30-05-2013 дата публикации

Deer attractant and nutrient

Номер: US20130136821A1
Автор: Edgar R. Welch, JR., Roger Rudd
Принадлежит: Individual

The embodiments of the Deer Attractant and Nutrient is a deer attractant and feed comprising rice hulls; calcium carbonate; manganese; copper sulfate; zinc sulfate; trace amounts of cobalt carbonate; EDDI; mono DICAL; selenium; and power sweet. Because of the balanced nutritional components of the Deer Attractant and Nutrient the product enhances overall deer growth including antler growth in bucks. The Deer Attractant and Nutrient also acts as a deer attractant, causing the deer to move toward a supply of the attractant.

Подробнее
Номер записи: 30
13-06-2013 дата публикации

Anti-Protozoal for Apicomplexan Protozoa

Номер: US20130150315A1
Автор: Kline Mary C.
Принадлежит:

The invention comprising the heretofore veterinary anti-protozoal decoquinate and one or both of a redox drug or macrolide drug for prophylaxis or treatment of and other Apicomplexan protozoa infections in humans. The decoquinate or its metabolite kill certain life stages of . The redox and macrolide drugs treat life stages and forms of that are not susceptible to the decoquinate. 1babesiababesia. A drug for prophylaxis or treatment of in humans , including sequestered in polymicrobial biofilms and plaque , comprising decoquinate: ethyl 6-decoxy-7-ethoxy-4-oxo-1H-quinoline-3-carboxylate [18507-89-6]; and a redox-active drug , or pharmaceutically acceptable salts thereof.2. The drug in wherein the redox-active drug is metronidazole: 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; or pharmaceutically acceptable salts thereof.3. The drug in wherein the redox-active drug is artemisinin or a derivative of artemisinin claim 1 , or pharmaceutically acceptable salts thereof.4babesiababesia. A drug for prophylaxis or treatment of in human claim 1 , including sequestered in polymicrobial biofilms and plaque claim 1 , comprising the drug in and a macrolide drug claim 1 , or pharmaceutically acceptable salts thereof.5. The drug in wherein the macrolide drug is azithromycin: (2R claim 4 ,3S claim 4 ,4R claim 4 ,5R claim 4 ,8R claim 4 ,10R claim 4 ,11R claim 4 ,12S claim 4 ,13S claim 4 ,14R)-11-[(2S claim 4 ,3R claim 4 ,4S claim 4 ,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3 claim 4 ,4 claim 4 ,10-trihydroxy-13-[(2R claim 4 ,4R claim 4 ,5S claim 4 ,6S)-5-hydroxy-4-methoxy-4 claim 4 ,6-dimethyloxan-2-yl]oxy-3 claim 4 ,5 claim 4 ,6 claim 4 ,8 claim 4 ,10 claim 4 ,12 claim 4 ,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one; or pharmaceutically acceptable salts thereof.6. The drug in wherein the macrolide drug is clarithromycin: (3R claim 4 ,4S claim 4 ,5S claim 4 ,6R claim 4 ,7R claim 4 ,9R claim 4 ,11R claim 4 ,12R claim 4 ,13S claim 4 ,14R)-6-[(2S claim 4 ,3R claim ...

Подробнее
Номер записи: 31
20-06-2013 дата публикации

Method for the prevention of chronic inflammation associated diseases

Номер: US20130156860A1
Автор: Fabien De Meester
Принадлежит: BNLfood Investments SARL

The present invention is related to a method for the prevention and possibly the treatment of chronic diseases, preferably inflammatory associated chronic diseases that may affect an animal including a human, by the administration of a sufficient amount of a (functional) food or feed to the diet of this animal.

Подробнее
Номер записи: 32
20-06-2013 дата публикации

Method of increasing the milk and/or meat quantity of silage-fed animals

Номер: US20130156932A1
Автор: Annette Freund, Charles Rice, Egon Haden, Gary Fellows, Jerry Minore, Jim Vandecoevering, Paul M. Vassalotti, Thomas Garfield
Принадлежит: BASF SE

The present invention relates to a method of increasing the milk and/or meat quantity of silage-fed animals comprising the steps: a) treating plants and/or propagules and/or sites where the plants are growing or are to grow with at least one strobilurin compound b) producing silage from the plants treated according to step a) c) feeding the milk and/or meat producing animals with the silage produced according to step b) made from the plants treated according to step a). Furthermore, the present invention relates to silage for feeding animals, produced from plants treated with at least one strobilurin compound prior to producing said silage. In addition, the present invention relates to the use of at least one strobilurin compound to increase the milk quantity of silage-fed milk-producing animals. Moreover, the present invention relates to the use of at least one strobilurin compound to increase the meat quantity of silage-fed meat-producing animals.

Подробнее
Номер записи: 33
04-07-2013 дата публикации

Regional suet compositions

Номер: US20130171291A1
Автор: Gretchen Lynn WHITE, Tony Dale KEMP
Принадлежит: SMG Brands Inc

Suet compositions intrinsically attractive to desirable birds in a particular region (e.g., northeast, southeast, midwest, southwest, and west) and which attract more desirable birds than other suet compositions. The suet compositions comprise tallow, peanuts, and corn in combination with black oil sunflower seeds, sunflower chips, white millet, and almonds; black oil sunflower seeds, sunflower chips, white millet, and pumpkin seeds; black oil sunflower seeds, sunflower chips, white millet, and safflower; dough mix and red millet, or dough mix and pecans.

Подробнее
Номер записи: 34
04-07-2013 дата публикации

ROFLUMILAST COMPOSITIONS FOR THE TREATMENT OF COPD

Номер: US20130172303A1
Автор: Freire Jose, Qian Xiaozhong, Scott Colin
Принадлежит: FOREST LABORATORIES HOLDINGS LTD.

The present invention relates to pharmaceutical compositions comprising roflumilast in combination with a corticosteroid and/or a leukotriene receptor antagonist. The invention also relates to the use of such compositions for the treatment of Chronic Obstructive Pulmonary Disorder (COPD). 1. A pharmaceutical composition comprising roflumilast or a pharmaceutically acceptable salt , ester , prodrug , or pharmaceutically acceptable salts of esters or prodrugs , or N-oxide thereof in combination with a corticosteroid or a pharmaceutically acceptable salt , ester , prodrug , or pharmaceutically acceptable salt of ester or prodrug thereof and a pharmaceutically acceptable excipient.2. The composition of claim 1 , wherein the corticosteroid is selected from the group consisting of dexamethasone claim 1 , prednisone and budesonide.3. The composition of claim 2 , wherein the corticosteroid is budesonide.4. A pharmaceutical composition comprising roflumilast or a pharmaceutically acceptable salt claim 2 , ester claim 2 , prodrug claim 2 , or pharmaceutically acceptable salts of esters or prodrugs claim 2 , or N-oxide thereof in combination with a leukotriene receptor antagonist or a pharmaceutically acceptable salt claim 2 , ester claim 2 , prodrug claim 2 , or pharmaceutically acceptable salt of ester or prodrug thereof and a pharmaceutically acceptable excipient.5. The composition of claim 4 , wherein the leukotriene receptor antagonist is montelukast.6. The composition of claim 4 , comprising 500 μg of the roflumilast or pharmaceutically acceptable salt claim 4 , ester claim 4 , prodrug claim 4 , or pharmaceutically acceptable salts of esters or prodrugs claim 4 , or N-oxide thereof.7. The composition of claim 4 , comprising 10 mg of the leukotriene receptor antagonist or pharmaceutically acceptable salt claim 4 , ester claim 4 , prodrug claim 4 , or pharmaceutically acceptable salt of ester or prodrug thereof.8. An oral dosage form comprising the composition of .9. An ...

Подробнее
Номер записи: 35
18-07-2013 дата публикации

COMBINATION OF SILOXANE AND ACTIVE INGREDIENT FOR TREATING DENTAL DISORDER

Номер: US20130184239A1
Автор: Schulz Hans H.
Принадлежит: BAYER INNOVATION GMBH

The invention relates to a pharmaceutical composition comprising a siloxane according to general formula (I)< 2. A composition according to claim 1 , wherein R means —CH claim 1 , Rand Rtogether form a (2n)-membered ring and n is an integer of from 3 to 6.3. A composition according to claim 1 , wherein the siloxane is octamethylcyclotetrasiloxane.4. A composition according to claim 1 , wherein the composition is administered prior to claim 1 , simultaneous with and/or subsequent to the pharmacologically active ingredient.5. A composition according to claim 1 , wherein the composition either comprises the pharmacologically active ingredient in combination with the siloxane according to formula (I) claim 1 , or the pharmacologically active ingredient comprises a second claim 1 , separate pharmaceutical composition.6. A composition according to claim 1 , wherein administration of the composition and/or of the pharmacologically active ingredient is capable of being topically and/or locally.7. A composition according to claim 1 , wherein administration of the composition is capable of improving penetration of the pharmacologically active ingredient into hard tissue.8. A composition according to claim 1 , wherein the pharmacologically active ingredient is an antibiotic.9. A composition according to claim 8 , wherein the antibiotic is a gyrase inhibitor.10. A composition according to claim 8 , wherein the antibiotic is a fluoroquinolone.11. A composition according to claim 8 , wherein the antibiotic is selected from the group consisting of doxycyclin claim 8 , minocyclin claim 8 , moxifloxacin and the physiologically acceptable salts thereof.12. A composition according to claim 1 , wherein a relative molar ratio of siloxane according to formula (I) and pharmacologically active ingredient is >1:1.13. A composition according to claim 1 , wherein the dental disorder is selected from the group consisting of tooth decay claim 1 , caries claim 1 , endodontic disorders and ...

Подробнее
Номер записи: 36
25-07-2013 дата публикации

TREATMENT OF SYMPTOMS ASSOCIATED WITH MENOPAUSE

Номер: US20130191934A1
Автор: Johnson Philip L., Shekhar Anantha
Принадлежит: Indiana University Research and Technology Corpora

A method for treating symptoms associated with a dramatic reduction in reproductive hormone levels is provided, particularly in menopausal women and breast cancer survivors undergoing aromatase inhibitor therapy. The method comprises administered to a subject an inhibitor of orexin activity in an amount sufficient to reduce or decrease onset, progression, severity, frequency, duration or probability of one or more such symptoms. A method of detecting compounds having activity for relieving menopausal symptoms is also provided. 1. A method of treating a female patient for menopausal symptoms , said method comprising the step ofadministering to said patient a composition comprising an inhibitor of orexin activity, in an amount sufficient to prevent the onset, or reduce the severity, frequency or duration of said menopausal symptoms.2. The method of further comprising the step of identifying women with below average estrogen levels claims 1 , wherein such women are administered said composition prophylactically or in response to symptoms.3. The method of wherein the composition comprises an ORX1 receptor antagonist.4. The method of wherein the composition comprises an ORX2 receptor antagonist.5. The method of wherein the composition comprises ORX1 and ORX2 receptor antagonist activity.6. The method of wherein the composition comprises an orexin inhibitor selected from the group consisting of SB334867 claim 1 , MK4305 and Almorexant.7. The method of wherein the patient is receiving aromatase inhibitor therapy.8. The method of wherein the patient is menopausal.9. A method of treating a woman to prevent or reduce the severity claim 1 , frequency or duration of hot flashes claim 1 , said method comprising the steps ofidentifying women that have below average estrogen levels;administering to woman having below average estrogen levels a composition comprising an orexin inhibitor.10. The method of wherein the orexin inhibitor interferes with ORX receptor activity.11. The ...

Подробнее
Номер записи: 37
08-08-2013 дата публикации

Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase

Номер: US20130203805A1
Автор: Arend Michael P., Flippin Lee A., Guenzler-Pukall Volkmar, Klaus Stephen J., Lin Al Y., Melekhov Alex, Neff Thomas B., Wang Qingjian
Принадлежит: FibroGen, Inc.

The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds. 1. A method for treating anemia in a subject , the method comprising administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.2. The method of claim 1 , wherein the subject is a subject having chronic kidney disease.3. The method of claim 1 , wherein the compound is selected from the group consisting of a heterocyclic carboxamide claim 1 , a phenanthroline claim 1 , and a hydroxamate.4. The method of claim 1 , wherein the compound is a heterocyclic carboxamide.5. The method of claim 1 , wherein the subject is undergoing or is at risk for undergoing kidney dialysis.6. The method of claim 1 , wherein the compound is delivered orally.7. The method of claim 2 , wherein the subject is undergoing or is at risk for undergoing kidney dialysis. This application claims the benefit of U.S. application Ser. No. 12/932,151 filed 17 Feb. 2011; U.S. application Ser. No. 11/406,023 filed 17 Apr. 2006; U.S. application Ser. No. 10/313,643, filed 6 Dec. 2002; U.S. Provisional Application Ser. No. 60/349,659 filed 16 Jan. 2002; U.S. Provisional Application Ser. No. 60/386,488, filed 5 Jun. 2002; U.S. Provisional Application Ser. No. 60/337,082, filed 6 Dec. 2001: and U.S. Provisional Application Ser. No. 60/359,683, filed 25 Feb. 2002; each of which is incorporated by reference herein in its entirety.The present invention relates to methods for increasing endogenous erythropoietin, ex vivo and in vivo, and to compounds that can be used in the methods.Erythropoietin (EPO), a naturally occurring hormone, stimulates the production of red blood cells ( ...

Подробнее
Номер записи: 38
15-08-2013 дата публикации

Methods and compositions for stimulating a felidae t1r receptor

Номер: US20130209625A1
Автор: Bruce Bryant, Joseph G. Brand
Принадлежит: MONELL CHEMICAL SENSES CENTER, Specialites Pet Food SAS

Provided herein are methods for stimulating the T1R1/T1R3 receptor comprising contacting the receptor with pyrophosphate and one or more amino acids. Also provided, is a Felidae food product comprising pyrophosphate and one or more amino acids. Methods for determining the pyrophosphate-augmented activity of a test compound on the T1R1/T1R3 receptor are also described, as well as methods for adjusting the food formulation for Felidae.

Подробнее
Номер записи: 39
22-08-2013 дата публикации

Composite animal feed compact

Номер: US20130217785A1
Автор: Robert L. Heimann
Принадлежит: Enginuity Worldwide LLC

An animal feed compact is provided by the present disclosure that includes a body having a various feed composition and an adhesive additive. The adhesive additive includes a starch and a hydroxide. Further additives may also be provided, which include any edible/digestible alfalfa meal, sunflower meal grain, ruffage [roughage], soybean meal wheat mids, hay, stover, whey dicalcium phosphate, limestone molasses, minerals, vitamins and medication. Various geometries and compositions for the biomass fuel compact are also provided by the present disclosure.

Подробнее
Номер записи: 40
29-08-2013 дата публикации

PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF

Номер: US20130224293A1
Автор: CAESAR, DAS LAURA, Dokou Eleni, FAWAZ MAJED, GU CHONG-HUI, HURTER PATRICIA NELL, ISRANI MEGHNA JAI, JAMZAD SHAHLA, JOHNSTON Meghan M., JR. John P., KNEZIC Dragutin, KUZMISSION ANDREW G., WANG HONGREN
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to pharmaceutical compositions containing a solid dispersion of N—[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. 1. A pharmaceutical composition comprising:a solid dispersion of amorphous or substantially amorphous Compound 1 in an amount of about 30 to about 50 percent by weight of the pharmaceutical composition;sucralose in an amount of between about 1.5 wt % to about 2.5 wt % percent by weight of the pharmaceutical composition;croscarmellose sodium in an amount from about 4 to about 8 percent of by weight of the pharmaceutical composition;colloidal silicon dioxide in an amount from about 0.5 wt % to about 1.5 wt % percent by weight of the pharmaceutical composition;magnesium stearate in an amount from about 0.5 wt % to about 1.5 wt % percent by weight of the pharmaceutical composition; andone or more fillers, collectively, in an amount of about 30 to about 60 percent of by weight of the pharmaceutical composition.2. The pharmaceutical composition of claim 1 , wherein the one or more fillers comprises mannitol.3. The pharmaceutical composition of claim 1 , wherein the one or more fillers comprise lactose.4. The pharmaceutical composition of claim 3 , wherein the filler comprises mannitol and lactose in a ratio of about 3:1 mannitol to lactose.5. The pharmaceutical composition of claim 3 , wherein the filler comprises mannitol and lactose in a ratio of about 1:1 mannitol to lactose.6. The pharmaceutical composition of claim 3 , wherein the filler comprises mannitol and lactose in a ratio of about 1:3 mannitol to lactose.7. The pharmaceutical composition of claim 1 , wherein the one or more fillers comprises mannitol in an amount of about 13.5 ...

Подробнее
Номер записи: 41
29-08-2013 дата публикации

Process to improve feed efficiency and carcass characteristics of animals

Номер: US20130224320A1
Автор: Joan Torrent Campmany
Принадлежит: Joan Torrent Campmany

This invention relates to a process to improve the feed efficiency and carcass characteristics of an animal. The process of this invention can be used to decrease the cost of animal diets, to improve performance of animals and to improve the percentage of carcass in animals.

Подробнее
Номер записи: 42
29-08-2013 дата публикации

Fermentation process to produce natural carotenoids and carotenoid-enriched feed products

Номер: US20130224333A1
Автор: Ananda Nanjundaswamy, Praveen V. Vadlani
Принадлежит: Kansas State University

Methods of fortifying animal feeds nutrients typically lacking therefrom through the action of microorganisms are provided. Fermentation of animal feed materials with selected microorganisms, such as certain varieties of red yeasts, are shown to fortify the feed materials with natural carotenoids. Further, in certain embodiments, these methods can result in an increase in levels of nutritionally beneficial fatty acids, and a decrease in dietary fiber and nitrogen levels.

Подробнее
Номер записи: 43
05-09-2013 дата публикации

Means to Culture Cochineal Insects in an Artificial Medium

Номер: US20130228126A1
Автор: Constance M. Hendrickson, Denise Lynn Merkle
Принадлежит: Badderloch Woad Inc

A method is provided for culturing cochineal insects. In accordance with the method, a medium is created ( 101 - 109 ) from a mixture comprising a plant or cactus additive and a polymeric material. The medium is then inoculated ( 111 ) with a species selected from the group consisting of the genus Dactylopius.

Подробнее
Номер записи: 44
05-09-2013 дата публикации

Enhanced bioavailable iodine molecules

Номер: US20130230619A1
Автор: Peter A. Stark
Принадлежит: Zinpro Corp

This invention relates to supplementation of the diets of domesticated animals (livestock and poultry) with iodine in an enhanced bioavailable manner, that is to say the iodine is more available to the animal than when using conventional sources of iodine, such as calcium iodate. The supplementary compound are alpha amino acid metal iodide complexes.

Подробнее
Номер записи: 45
19-09-2013 дата публикации

Antidiabetic Solid Pharmaceutical Compositions

Номер: US20130243865A1
Автор: Higgins Linda, Lanfear Dennis, Lee Kathleen M.
Принадлежит: Intekrin Therapeutics, Inc., INC.

Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-Y suitable for oral dosage to treat subjects having PPAR-Y mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-Y mediated condition. 2. (canceled)3. (canceled)4. The solid pharmaceutical composition of wherein the compound is present as a salt thereof selected from the group consisting of benzenesulfonate salt claim 1 , hydrochloride salt claim 1 , hydrobromide salt claim 1 , and p-toluenesulfonate salt.5. (canceled)6. The solid pharmaceutical composition of in the form of a tablet or powder claim 1 , including an encapsulated powder.7. The solid pharmaceutical composition of provided as a unit dosage form.8. The solid pharmaceutical composition of prepared by a process which comprises the steps of (a) micronizing the compound of formula (I); and (b) preparing a wet granulation of the micronized compound in combination with one or more pharmaceutically acceptable excipients.10. (canceled)11. (canceled)12. (canceled)13. The solid pharmaceutical composition of wherein the compound for formula (I) is present as the benzenesulfonate salt and wherein the benzenesulfonate salt is present in an amount of between about 0.1 to about 10.0 mg.14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. (canceled)20. (canceled)22. The method of comprising the steps of:(a) mixing micronized particles of the compound of formula (I) with one or more excipients to form a powder blend;(b) adding a granulating solution to the powder blend obtained in step (a), and mixing the solution and powder blend to form wet granules;(c) drying the wet granules obtained in step (b) to form dry granules;(d) milling the dry granules obtained in step (c);(e) blending the milled dry granules obtained in step (d) with one or more excipients to form a blend constituting the final composition of the solid pharmaceutical composition; and(f) ...

Подробнее
Номер записи: 46
19-09-2013 дата публикации

Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity

Номер: US20130245024A1
Автор: Higgins Linda, Lanfear Dennis
Принадлежит:

The present invention relates to pharmaceutical compositions and methods for the treatment of diabetes, obesity or disorders related to diabetes or obesity. The compositions comprise a combination of a particular PPARγ agonist and a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor. The methods include the administration of the combination of a particular PPARγ agonist and a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor. 2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable salt of the compound is a benzenesulfonate salt claim 1 , a hydrochloride salt or a p-toluenesulfonate salt of the compound.3. The pharmaceutical composition of claim 1 , wherein the DPP-IV inhibitor is selected from the group consisting of vildagliptin claim 1 , sitagliptin claim 1 , saxagliptin claim 1 , PSN9301 claim 1 , SYR 322 and SYR 472.4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable diluent claim 1 , excipient or carrier.5. The pharmaceutical composition of claim 1 , wherein the composition comprises 0.5 mg of the compound of formula (I).6. The pharmaceutical composition of claim 1 , wherein the composition comprises 1 mg of compound of formula (I).7. The pharmaceutical composition of claim 1 , wherein the composition comprises 2 mg of compound of formula (I).8. The pharmaceutical composition of claim 1 , wherein the composition comprises 3 mg of compound of formula (I).9. The pharmaceutical composition of claim 1 , wherein the composition comprises 4 mg of compound of formula (I).10. The pharmaceutical composition of claim 1 , wherein the composition comprises 5 mg of compound of formula (I).12. The method of wherein said subject is human.13. The method of wherein said condition is diabetes.14. The method of wherein said condition is obesity.15. The method of wherein said disorder related to diabetes or obesity is selected from the group consisting of ...

Подробнее
Номер записи: 47
03-10-2013 дата публикации

Methods for therapeutic treatment of benign prostatic hypertrophy (bph)

Номер: US20130261057A1
Автор: David L. KLEINBERG
Принадлежит: Individual

Therapeutic methods for treatment of benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I) are described herein. Methods encompass the use of IGF-I antagonists, as well as the use of compounds that lower the effective level of IGF-I or interfere with post receptor effects of IGF-I action in the prostate.

Подробнее
Номер записи: 48
03-10-2013 дата публикации

Use of essential oil compounds as histomonastat

Номер: US20130261191A1
Автор: Didier Archain, Marco Frehner, Riccardo Losa
Принадлежит: DSM IP ASSETS BV

Essential oil compounds, such as p-cymene, thymol, salicylaldehyde, tea tree oil, peppermint oil, cuminaldehyde, cinnamic acid, cinnamic alcohol, farnesal and farnesylacetone, especially 2-decenal and nerolidol when added to feed or drinking water to combat histomonas , a single cell protozoan organism that is an intestinal parasite infecting both vertebrates and invertebrates.

Подробнее
Номер записи: 49
10-10-2013 дата публикации

Method for desalting animal tissue

Номер: US20130266686A1
Автор: Marnix Rogier Morskate
Принадлежит: Vion Ingredients Nederland Holding BV

The present invention relates to a method for desalting tissue originating from animals. In particular, the present invention provides a method for desalting mucosa tissue, notably mucosa tissue originating from bovine or porcine. The invention also provides a method for preparing animal feed supplement or additive enriched in nutritional elements readily available to the animal, in particular to the young animal, for example young piglets, chickens, calves or aqua species. The invention also provides a low-salt content or a salt-free animal feed supplement and a feeding or growing method using the same.

Подробнее
Номер записи: 50
07-11-2013 дата публикации

Dehydrated castor oil as an animal feed supplement

Номер: US20130295223A1
Автор: Patrick V. Bonsignore
Принадлежит: NPD Investments Inc

The present invention relates to a method for improving the fat firmness and meat quality of a meat animal and/or altering the ratio of saturated fatty acids to unsaturated fatty acids in meat by administering to a meat animal (e.g., pig) a composition comprising an amount of dehydrated castor oil that is effective to improve the quality indices of the animal's meat.

Подробнее
Номер записи: 51
07-11-2013 дата публикации

QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION

Номер: US20130296365A1
Автор: Bando Masashi
Принадлежит:

A pharmaceutical composition comprising a compound represented by the formula (I) or pharmaceutically acceptable salt thereof or solvate thereof, and a basic substance is excellent in dissolution, is stable even after a long term storage, and is useful as a preventive or therapeutic agent against a tumor: 112-. (canceled)13. A pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate and an alkaline earth metal carbonate.14. The pharmaceutical composition according to claim 13 , further comprising a disintegrating agent.15. The pharmaceutical composition according to claim 13 , wherein the alkaline earth metal carbonate is calcium carbonate.16. The pharmaceutical composition according to claim 15 , further comprising a disintegrating agent.17. The pharmaceutical composition according to claim 13 , wherein the alkaline earth metal carbonate is magnesium carbonate.18. The pharmaceutical composition according to claim 17 , further comprising a disintegrating agent.19. The pharmaceutical composition according to claim 14 , wherein the disintegrating agent is at least one agent selected from carmellose sodium claim 14 , carmellose calcium claim 14 , carboxymethyl starch sodium claim 14 , croscarmellose sodium claim 14 , low-substituted hydroxypropylcellulose and crospovidone.20. The pharmaceutical composition according to claim 13 , wherein said pharmaceutical composition is in a capsule dosage form.21. The pharmaceutical composition according to claim 15 , wherein said pharmaceutical composition is in a capsule dosage form.22. The pharmaceutical composition according to claim 17 , wherein said pharmaceutical composition is in a capsule dosage form.23. A pharmaceutical composition comprising:4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate; andmeans for achieving dissolution of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7- ...

Подробнее
Номер записи: 52
21-11-2013 дата публикации

STABLE FORMULATIONS OF PITAVASTATIN

Номер: US20130310420A1
Автор: Chang Chi-Tai, HSIAO YU-CHIEN, Lin Che-Chin
Принадлежит: Orient Pharma Co., Ltd.

Disclosed is a pharmaceutical composition comprising pitavastatin, or its salt or ester and MgO, of which the aqueous solution or dispersion has pH of from 10 to 10.8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long. 1. A pharmaceutical composition consisting essentially of Pitavastatin , or its salt , solvate or ester , about 3% to about 20% of magnesium oxide by weight , and a pharmaceutically acceptable carrier.2. The pharmaceutical composition of wherein an aqueous solution or dispersion of the pharmaceutical composition has pH of from 10.0 to 10.8.3. The pharmaceutical composition of claim 1 , wherein said composition does not include pH regulators.4. The pharmaceutical composition of wherein the composition further comprises at least one material selected from the group consisting of excipients claim 1 , disintegrators claim 1 , binders and lubricants.5. The pharmaceutical composition of wherein the composition is formulated for oral application.6. The pharmaceutical composition of wherein the excipients comprise microcrystalline cellulose claim 4 , lactose claim 4 , mannitol claim 4 , starch claim 4 , or combination thereof.7. The pharmaceutical composition of wherein the disintegrators comprise sodium starch glycolate claim 4 , kollidon CL claim 4 , croscarmellose sodium claim 4 , hydroxypropyl cellulose claim 4 , or combination thereof.8. The pharmaceutical composition of wherein the binders comprise polyvinylpyrrolidone.9. The pharmaceutical composition of wherein the polyvinylpyrrolidone is PVP K30.10. A pharmaceutical composition comprising Pitavastatin claim 8 , or its salt claim 8 , solvate or ester claim 8 , about 3% to about 20% of magnesium oxide by weight claim 8 , and a pharmaceutically acceptable carrier wherein an aqueous solution or dispersion of said pharmaceutical composition has pH of from 10.0 to 10.8. This application claims the benefit of U.S. provisional ...

Подробнее
Номер записи: 53
28-11-2013 дата публикации

PDE-10 INHIBITORS

Номер: US20130317025A1
Автор: Chesworth Richard, Ripka Amy, Shapiro Gideon
Принадлежит:

Vicinal substituted cyclopropyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function, for example neurological, neurodegenerative and psychiatric disorders including, but not limited to, those comprising cognitive deficits or schizophrenic symptoms. 178-. (canceled)80. The pharmaceutical composition of claim 79 , wherein Ris hydrogen or C-C.81. The pharmaceutical composition of claim 79 , wherein Ris hydrogen or C-Calkyl.82. The pharmaceutical composition of claim 79 , wherein Ris hydrogen claim 79 , halogen claim 79 , C-Calkyl claim 79 , C-Ccycloalykl claim 79 , C-Calkoxy claim 79 , C-Ccycloalkyloxy claim 79 , cyano or alkylsulfonyl.83. The pharmaceutical composition of claim 79 , wherein Ris hydrogen claim 79 , halogen claim 79 , C-Calkyl claim 79 , C-Ccycloalykl claim 79 , C-Calkoxy claim 79 , C-Ccycloalkyloxy claim 79 , cyano or alkylsulfonyl.84. The pharmaceutical composition of claim 79 , wherein Y is C-Ccycloalykl claim 79 , C-Ccycloalkylalkyl claim 79 , C-Ccycloalkylalkoxy claim 79 , heterocycloalkyl claim 79 , or heterocycloalkyloxy.85. The pharmaceutical composition of claim 79 , wherein X is alkyl claim 79 , phenyl or heteroaryl.86. The pharmaceutical composition of claim 79 , wherein HET is a monocyclic heterocycloalkyl.87. The pharmaceutical composition of claim 86 , wherein HET is a monocyclic heterocycloalkyl having only 6 ring atoms.88. The pharmaceutical composition of claim 86 , wherein HET is a monocyclic heterocycloalkyl having only 5 ring atoms.89. The pharmaceutical composition of claim 79 , wherein HET is imidazolyl claim 79 , thiazolyl claim 79 , oxazolyl claim 79 , pyridinyl claim 79 , pyrmidinyl claim 79 , pyrazinyl claim 79 , triazolyl claim 79 , pyrazolyl claim 79 , ...

Подробнее
Номер записи: 54
05-12-2013 дата публикации

Animal feeds and processes for producing same

Номер: US20130323365A1
Автор: Nick Thomas
Принадлежит: SUPREME PETFOODS Ltd

The present invention relates to animal feed and processes for manufacturing the same. In particular, this invention relates to a high fibre, low density, mono-component (monoforage) product with high concentrations of long fibre particles derived from forage material, for feeding to pets and other animals and methods for producing the same.

Подробнее
Номер записи: 55
12-12-2013 дата публикации

Pharmaceutical Compositions and Administrations Thereof

Номер: US20130331412A9
Автор: Burton William Lawrence, Huang Chien-Jung, Negulescu Paul Adrian, Van Goor Fredrick F., Yu Haihui
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. 1. A method of treating a CFTR mediated disease in a human comprising administering Compound 1 to a patient possessing a human CFTR mutation selected from G178R , G551S , G970R , G1244E , S1255P , G1349D , S549N , S549R , S1251N , E193K , F1052V and G1069R.2. The method of claim 1 , wherein the human CFTR mutation is selected from G178R claim 1 , G551S claim 1 , G970R claim 1 , G1244E claim 1 , S1255P claim 1 , G1349D claim 1 , S549N claim 1 , S549R and S1251N.3. The method of claim 1 , wherein the human CFTR mutation is selected from E193K claim 1 , F1052V and G1069R.4. A method of treating a CFTR mediated disease in a human comprising administering Compound 1 to a patient possessing a human CFTR mutation selected from R117C claim 1 , D110H claim 1 , R347H claim 1 , R352Q claim 1 , E56K claim 1 , P67L claim 1 , L206W claim 1 , A455E claim 1 , D579G claim 1 , S1235R claim 1 , S945L claim 1 , R1070W claim 1 , F1074L claim 1 , D110E claim 1 , D1270N and D1152H.5. A method of treating a CFTR mediated disease in a human comprising administering Compound 1 to a patient possessing a human CFTR mutation selected from G178R claim 1 , G551S claim 1 , G970R claim 1 , G1244E claim 1 , S1255P claim 1 , G1349D claim 1 , S549N claim 1 , S549R claim 1 , S1251N claim 1 , E193K claim 1 , F1052V and G1069R claim 1 , and a human CFTR mutation selected from ΔF508 claim 1 , R117H claim 1 , and G551D.6. The method of claim 5 , wherein Compound 1 is administered to a patient possessing a human CFTR mutation selected from G178R claim 5 , G551S claim 5 , G970R claim 5 , G1244E claim 5 , S1255P claim 5 , G1349D claim 5 , S549N claim 5 , S549R and S1251N claim 5 , and a human CFTR ...

Подробнее
Номер записи: 56
26-12-2013 дата публикации

Gap Junction-Enhancing Agents for Treatment of Necrotizing Enterocolitis and Inflammatory Bowel Disease

Номер: US20130345154A1
Автор: HACKAM DAVID J.
Принадлежит:

The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation. 1. A method of treating necrotizing enterocolitis in a subject in need of such treatment comprising administering to the subject an effective amount of a gap junction enhancing agent.2. The method of where the gap junction enhancing agent is a quinoline derivative.3. The method of where the gap junction enhancing agent is a peptide.4. The method of where the peptide has a sequence selected from the group of SEQ ID NO:1-31.4. The method of where the gap junction enhancing agent is a peptide analog.5. The method of which is Rotigaptide.6. A method of treating inflammatory bowel disease in a subject in need of such treatment comprising administering to the subject an effective amount of a gap junction enhancing agent.7. The method of where the gap junction enhancing agent is a quinoline derivative.8. The method of where the gap junction enhancing agent is a peptide.9. The method of where the peptide has a sequence selected from the group of SEQ ID NO:1-31.10. The method of where the gap junction enhancing agent is a peptide analog.11. The method of which is Rotigaptide.12. A method of reducing the risk of occurrence of necrotizing enterocolitis in a subject in need of such treatment comprising administering to the subject an effective amount of a gap junction enhancing agent.13. The method of where the gap junction enhancing agent is a quinoline derivative.14. The method of where the gap junction enhancing agent is a ...

Подробнее
Номер записи: 57
02-01-2014 дата публикации

Pet food frosting/icing composition

Номер: US20140004245A1
Автор: Andrew E. Colsky
Принадлежит: Individual

A yogurt based pet food composition includes a dry ingredients mixture composed of dry powdered yogurt, dry powdered maltodextrin, dry powdered starch, and dry powdered guar gum.

Подробнее
Номер записи: 58
23-01-2014 дата публикации

Process for the production of a powdered composition, the powdered composition obtained thereby and uses thereof

Номер: US20140023772A1
Автор: Geertje Katrien Huijs, Joep VAN DEN BRENK, Johan Michiel Adriaan Bosman
Принадлежит: Nutricia NV

The present invention relates to a process for the production of a powdered composition from a liquid composition comprising fat, protein or both, to the powdered composition obtained thereby and products containing said powdered composition.

Подробнее
Номер записи: 59
30-01-2014 дата публикации

THERAPEUTIC AGENT FOR TUMOR

Номер: US20140031384A1
Автор: Funahashi Yasuhiro, Matsui Junji, Narita Yusuke
Принадлежит: Eisai R&D Management Co., Ltd.

A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): 2. (canceled)6. The method of claim 1 , comprising simultaneous administration of the compound represented by Formula (I) claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and the compound represented by Formula (II).7. The method of claim 1 , comprising separate administration of the compound represented by Formula (I) claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and the compound represented by Formula (II).8. The method of claim 1 , wherein the tumor is thyroid cancer claim 1 , lung cancer claim 1 , melanoma claim 1 , endometrial cancer claim 1 , gastric cancer claim 1 , bladder cancer claim 1 , renal cancer claim 1 , glioma claim 1 , liver cancer claim 1 , or ovarian cancer.9. The method of claim 1 , wherein the tumor is melanoma. The present invention relates to a therapeutic agent for tumor for combined use of a compound having a kinase inhibitory effect and a compound having a BRAF inhibitory effect. Particularly, the present invention relates to a therapeutic agent for tumor for combined use of a compound having a multi-tyrosine kinase inhibitory effect and N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide (PLX4032).wherein Ris Calkyl or Ccycloalkyl, Ris a hydrogen atom or Calkoxy, and Ris a hydrogen atom or a halogen atom.The compound represented by Formula (I) has anti-angiogenic actions (Patent Literature 1), inhibitory effects (Patent Literatures 2 to 5) against tyrosine kinases which are reported to be involved in malignant alteration of tumors (Non-Patent Literatures 1 to 5), and the like; and is known as a therapeutic agent for various tumors such as thyroid cancer, lung cancer, melanoma, endometrial cancer, gastric cancer, bladder cancer, renal cancer, glioma, liver cancer, and ovarian ...

Подробнее
Номер записи: 60
30-01-2014 дата публикации

SCREENING METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

Номер: US20140031389A1
Автор: Daniel Fanny, Ogier-Denis Eric, Pedruzzi Eric, Treton Xavier
Принадлежит: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MDEICALE)

The present invention relates to screening methods and pharmaceutical compositions for the treatment of inflammatory bowel disease. More particularly, the present invention relates to a method for screening a plurality of test substances useful for the prevention or treatment of an inflammatory bowel disease comprising the steps consisting of (a) testing each of the test substances for its ability to restore the integrated stress response and (b) and positively selecting the test substances capable of restoring said integrated stress response. A further aspect of the invention relates to an agent capable of restoring the integrated stress response (ISR) for use in the treatment of an inflammatory bowel disease. 1. A method for screening a plurality of test substances useful for the prevention or treatment of an inflammatory bowel disease comprising the steps of(a) testing each of the test substances for its ability to restore the integrated stress response and(b) positively selecting the test substances capable of restoring said integrated stress response.2. The method according to wherein step (a) of the screening method includes determining whether the test substancesi) increase the phosphorylation of eIF2a,ii) activate the expression of ATF4 gene,iii) activate the expression of one or more genes targeted by ATF4 as depicted in Table 1,iv) activate the kinases that promote eIF2a phosphorylation, orv) inhibit the dephosphorylation of phosphorylated eIF2a.3. The method according to wherein said method comprises the steps ofi) testing each of the test substances for its ability to increase phosphorylation of eIF2a, andii) identifying, as preventive or therapeutic agents for an inflammatory bowel disease, test substances which increase phosphorylation of eIF2a.4. The method according to wherein said method comprises the steps ofi) testing each of the test substances for its ability to inhibit the dephosphorylation of eΣF2a, andii) identifying, as preventive or ...

Подробнее
Номер записи: 61
30-01-2014 дата публикации

PITAVASTATIN-CONTAINING PREPARATION AND METHOD FOR PRODUCING SAME

Номер: US20140031390A1
Автор: Hamaguchi Nobuko, Hosaka Shouichi, NOZAWA Kenji, Okamura Yasufumi
Принадлежит: SAWAI PHARMACEUTICAL CO., LTD.

The present invention provides a pitavastatin-containing preparation containing pitavastatin or a pharmacologically acceptable salt thereof and at least one kind of a basic additive selected from the group consisting of basic magnesium compounds and basic calcium compounds, and an aqueous solution or an aqueous dispersion of the pitavastatin-containing preparation having a pH of more than 8 and 10 or less; and a method for producing a pitavastatin-containing preparation, including blending at least one kind of a basic additive selected from the group consisting of basic magnesium compounds and basic calcium compounds with pitavastatin or a pharmacologically acceptable salt thereof, to make an aqueous solution or an aqueous dispersion of the pitavastatin-containing preparation have a pH of more than 8 and 10 or less. 1. A pitavastatin-containing preparation comprising pitavastatin or a pharmacologically acceptable salt thereof and at least one kind of a basic additive selected from the group consisting of basic magnesium compounds and basic calcium compounds , and an aqueous solution or an aqueous dispersion of the pitavastatin-containing preparation having a pH of more than 8 and 10 or less.2. The pitavastatin-containing preparation according to claim 1 , wherein pitavastatin or the pharmacologically acceptable salt thereof is a pitavastatin calcium salt.3. The pitavastatin-containing preparation according to claim 1 , wherein the basic additive is a basic magnesium compound.4. The pitavastatin-containing preparation according to claim 3 , wherein the basic magnesium compound is at least one kind selected from the group consisting of magnesium hydroxide claim 3 , magnesium carbonate claim 3 , magnesium silicate and magnesium aluminometasilicate.5. The pitavastatin-containing preparation according to claim 1 , wherein the basic additive is a basic calcium compound.6. The pitavastatin-containing preparation according to claim 5 , wherein the basic calcium compound is ...

Подробнее
Номер записи: 62
06-02-2014 дата публикации

Method of Protecting Active Ingredients From Degradation During Pelleting

Номер: US20140037709A1
Автор: Bill L. Miller, Jill Davidson, Sarah E. Boucher
Принадлежит: Kemin Industries Inc

A system for the protection against degradation during pelleting of one or more physiologically or pharmacologically active substances, comprising compositions in the form of micro particles or granules, particularly for use in the zootechnical and/or veterinary field. The micro particles include a core which contains one or more substances having a pharmacological action, food supplements or diagnostic media, said one or more substances being characterized by the presence, within their chemical structure, of a basic functional group, specifically including an amine functional group. The core comprises also one or more carboxylic acids and/or their salts and eventually one or more excipients. Said core is coated by an outer layer of fats or waxes, and preferably by a mixture of glyceride of fatty acids.

Подробнее
Номер записи: 63
06-02-2014 дата публикации

Use of expanded constituents and manufacture of products therefrom

Номер: US20140037784A1
Автор: John Russell-Maynard
Принадлежит: Nestec SA

The present invention provides methods and products made thereby, wherein a pre-expanded constituent, including an edible constituent, is thermally treated to melt it, preferably in a dynamic process environment, to produce products ranging from high to quite low densities and from very strong to soft to apparently dry textures. The wide range of textures enables the provision of food products such as low calorie, digestible and safe, long duration pet food chews. Non-food products suitable for use in manufacture may also be produced. Cooking is preferably carried in an extruder, preferably at low moisture or in the total absence of added water. The methods of dynamic cooking reduce cost in a number of ways including but not limited to decreased process steps, increased throughput, decreased capital expenses and decreased raw product cost.

Подробнее
Номер записи: 64
13-02-2014 дата публикации

Methods and compositions for improving growth of meat-type poultry

Номер: US20140044700A1
Автор: Jason C.H. Shih
Принадлежит: North Carolina State University

The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, increasing feed digestibility, and decreasing mortality of immature and developing animals receiving animal feed. Methods of producing a crude keratinise enzyme extract and animal feed supplements for achieving the same are also provided.

Подробнее
Номер записи: 65
13-02-2014 дата публикации

TREATMENT METHODS OF COGNITIVE, EMOTIONAL AND MENTAL AILMENTS AND DISORDERS

Номер: US20140045884A1
Автор: Schultz Jack William
Принадлежит:

Methods for the treatment of cognitive, emotional and mental ailments using therapeutically effective amounts of compositions including leukotriene receptor antagonists, leukotriene synthesis inhibitors or leukotriene modifiers, zafirlukasts, montelukasts, other members of the family—lukasts, zileutons. 1. A method , comprising administering to a patient suffering from a family of mental , emotional and cognitive ailments a therapeutically effective amount of a composition affecting the ailment for a specified period of time for relief of the ailments.2. The method as claimed in wherein the composition is a leukotriene receptor antagonist.3. The method as claimed in wherein the composition is a leukotriene synthesis inhibitor.4. The method as claimed in wherein the composition is a leukotriene modifier.5. The method as claimed in wherein the composition is a montelukast.6. The method as claimed in wherein the composition is a zafirlukast.7. The method as claimed in wherein the composition is a zileuton.8. The method as claimed in wherein the composition is a member of the family—lukast.9. The method as claimed in wherein the composition is administered at an initial dosage of about 20-30 mg.10. The method as claimed in wherein additional dosages are administered at periodic intervals.11. The method as claimed in wherein the additional dosage is about 5 mg.12. The method as claimed in wherein the additional dosage is about 10 mg.13. The method as claimed in wherein the additional dosage is about 20 mg.14. The method as claimed in wherein the periodic interval is about every 2 hours.15. The method as claimed in wherein the periodic interval is about every 4 hours.16. The method as claimed in wherein the maximum daily dosage is about 40 mg.17. The method as claimed in wherein the maximum daily dosage is about 80 mg.18. The method as claimed in wherein the ailments result from mild permanent cognitive and short term memory loss.19. The method as claimed in wherein the ...

Подробнее
Номер записи: 66
27-02-2014 дата публикации

Food additive for ruminants based on eugenol and cinnamaldehyde

Номер: US20140056983A1
Автор: Christopher Kamel, François Gautier, Perry Doane, Sergio Calsamiglia
Принадлежит: ADM Alliance Nutrition Inc, AXIS FRANCE Sas

The invention concerns a composition based on a mixture of eugenol and cinnamaldehyde, as food additive for feeding ruminants. The composition may be incorporated in a food additive or a salt block. The eugenol and the cinnamaldehyde may be natural or identical natural constituents. Administering the composition of the food additive increases meat production and milk production.

Подробнее
Номер записи: 67
27-02-2014 дата публикации

Compositions and methods for controlling the weight of animals

Номер: US20140057017A1
Автор: Kim Gene Friesen, Ryan Michael Yamka
Принадлежит: Hills Pet Nutrition Inc

Compositions are provided comprising a balance between lysine and essential amino acids and metabolizable enemy. The compositions are useful in methods to prevent or treat obesity in an animal without concomitant loss of lean muscle mass. The compositions may also be user in methods to preserve or to cause a gain in lean muscle mass in an animal in need thereof.

Подробнее
Номер записи: 68
20-03-2014 дата публикации

Optimizing egg production characteristics via seawater mineralization

Номер: US20140079803A1
Автор: Edward E. Anderson, Neal Rye, Timothy E. Luberski
Принадлежит: LUBERSKI Inc (DBA HIDDEN VILLA RANCH)

Aspects for utilizing a seawater fluid to optimize egg-production characteristics are disclosed. In one aspect, a method is provided, which includes identifying a desired optimization, determining a corresponding seawater to non-seawater ratio, and generating a seawater fluid according to the ratio. An egg-cultivation method is also provided, which includes ascertaining a desired optimization, selecting a corresponding seawater to non-seawater ratio, and providing a seawater fluid comprising the ratio to a hen. In another egg-cultivation method, hens are provided with a mixed feed comprising a feed to seawater-mineralized produce ratio selected according to a desired optimization. A method to grow produce is also provided, which includes mineralizing soil with a seawater fluid comprising a seawater to non-seawater ratio corresponding to a preferred optimization. In another aspect, a method to produce feed is disclosed, which includes mixing feed with mineralized produce according to a ratio corresponding to a desired optimization.

Подробнее
Номер записи: 69
27-03-2014 дата публикации

Inhibiting microbial infections

Номер: US20140088144A1
Автор: Susan M. Egan
Принадлежит: University of Kansas

A method of inhibiting a microbial infection can include: providing a compound of the invention or prodrugs or pharmaceutically acceptable salts thereof; and administering the compound to a subject in a therapeutically effective amount to inhibit the microbial infection. The therapeutically effective amount can be sufficient to inhibit a biological activity of a transcriptional activator of the microbe. The inhibited transcriptional activator is an AraC bacterial transcriptional activator. The AraC bacterial transcriptional activator can be RhaS, RhaR, Rns, or VirF. The microbe can be selected from Vibrio, Pseudomonas , Enterotoxigenic E. coli , and Shigella.

Подробнее
Номер записи: 70
03-04-2014 дата публикации

Method of modulating the degree of adipose tissue deposited intramuscularly

Номер: US20140094512A1
Автор: John Michael Graettinger, Nikolas Gunkel, Thorsten Meyer
Принадлежит: Intervet Inc

The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in cattle by administration of a retinoic receptor antagonist or inverse agonist and compounds for use in such method.

Подробнее
Номер записи: 71
06-01-2022 дата публикации

PROTEIN RICH FOOD INGREDIENT FROM BIOMASS AND METHODS OF PRODUCTION

Номер: US20220000141A1
Автор: Domaille Peter, Dueppen Daniel G., Flatt James H., Rutt George C., Toledo Gerardo V.
Принадлежит:

The present invention provides a protein material and food ingredient from a sustainable and stable source. The sustainable and stable source of the food or food ingredient is cellular biomass, for example an algal or microbial biomass. The invention discloses that the cellular biomass can be subjected to a series of steps to derive the protein material and food or food ingredient, which has high nutritional content and has pleasing organoleptic properties. 1. A method of producing a protein composition from cellular biomass comprising cells from an organism of the Class Labyrinthulomycetes for use in a food product comprising:a) performing a pasteurization step on cellular biomass comprising cells from an organism of the Class Labyrinthulomycetes prior to lysing of the cells to produce a pasteurized biomass,b) subsequent to step a), subjecting the pasteurized biomass to an acid wash at a depressed pH of less than 4.5 for at least 10 minutes;lysing the cells of the biomass; andproducing the protein composition for use in a food product, wherein the protein composition has a protein content of at least 60% w/w.2. The method of wherein the acid wash comprises a depressed pH of less than 4.0 held for at least 20 minutes.3. The method of wherein the depressed pH is adjusted to about 3.5 and the depressed pH is held for about 30 minutes.4. The method of wherein after adjusting the pH to the depressed pH of less than 4.0 the pH is adjusted to a raised pH of greater than 4.0.5. The method of wherein the subjecting the biomass to the acid wash is by contacting said biomass with an inorganic acid.6. The method of wherein the inorganic acid is sulfuric acid or hydrochloric acid.7. The method of further comprising performing a delipidation step on the cellular biomass.8. The method of wherein the cellular biomass contains a protein composition and the method improves the organoleptic properties of the protein composition.9. The method of wherein the delipidation step is ...

Подробнее
Номер записи: 72
03-01-2019 дата публикации

Novel Microbial Biomass Based Feed Products

Номер: US20190000124A1
Автор: Coleman William J., Sefton Brian A.
Принадлежит:

Aquafeed, animal feed, and other food products, as well as nutritional and pharmaceutical compounds, chemicals and biomaterials are important commodities that can be produced at commercial scale by fermentation of microorganisms. The present invention provides a method for producing these valuable multi-carbon compounds from simple gas feedstocks, such as carbon dioxide, hydrogen and oxygen, by cultivating a consortium of microbial cells specially selected for this purpose in an aqueous culture medium. In addition to exploiting inexpensive feedstocks, such as waste industrial gas for this cultivation, the platform described herein also provides the advantage of removing carbon dioxide and other waste gases from industrial emissions, which would otherwise contribute to global climate change. Furthermore, the cultivation of a microbial consortium can provide highly nutritious components to a feed blend that might not be available from a monoculture. 1. A food or feed additive product comprising:a consortium of chemoautotrophic and photoautotrophic bacteria and heterotrophic microbes, the consortium including{'i': Cupriavidus, Methylococcus,', 'Rhodococcus,, 'chemoautotrophic bacteria from the genera or'}{'i': Rhodobacter, Rhodospirillum, Rhodopseudomonas,', 'Arthrospira, and, 'photoautotrophic bacteria from the genera or'}{'i': Bacillus, Bacteroides, Lactococcus, Leuconostoc, Pediococcus, Acidilactici, Pediococcus, Propionibacterium, Streptococcus, Bifidobacterium,', 'Lactobacillus., 'heterotrophic microbes from the genera or'}2. A method comprising:providing a consortium of chemoautotrophic and photoautotrophic bacteria and heterotrophic microbes within a system, the system including a fermentation vessel filled with an aqueous medium comprising the consortium, the fermentation vessel having an input port into which gaseous substrates are introduced into the aqueous medium, the fermentation vessel further having an exhaust port through which gases exit the ...

Подробнее
Номер записи: 73
07-01-2016 дата публикации

Composition, batter material using same, food or drink and feed, and method of producing composition

Номер: US20160000122A1
Автор: Isao Kobayashi, Junpei Kubota, Masaru Goto, Yuya Nagahata
Принадлежит: J Oil Mills Inc

A composition containing a starch at a content of equal to or higher than 75% by mass, wherein the composition contains a low molecular weight starch as the starch at a content of equal to or higher than 3% by mass and equal to or lower than 45% by mass, the low molecular weight starch being obtainable from a starch containing amylose at a content of equal to or higher than 5% by mass as a raw material, wherein a peak molecular weight of the low molecular weight starch is equal to or higher than 3×10 3 and equal to or lower than 5×10 4 , wherein a degree of swelling in cold water of the composition at 25 degrees C. is equal to or higher than 7 and equal to or lower than 20, and wherein a content of an oversieve fraction of a granulated material in the composition on 0.5 mm mesh is equal to or lower than 50% by mass.

Подробнее
Номер записи: 74
05-01-2017 дата публикации

Method of Increasing Feed Intake of an Animal

Номер: US20170000163A1
Автор: Zdenko Grajcar
Принадлежит: Once Innovations Inc

A method of increasing feed consumption in avian and aquatic life utilizing an artificial light source. For both avian and the aquatic life an enclosure is provided that houses the animal. An artificial lighting source is utilized to cause feed to emit light having a spectrum under 400 nm such that the animals locate and are attracted to the feed for consumption.

Подробнее
Номер записи: 75
07-01-2021 дата публикации

ANIMAL FEED ADDITIVE AND ANIMAL FEED

Номер: US20210000139A1
Автор: MAEKAWA Mayumi, Nakagawa Kazuki, UEHARA Akinori
Принадлежит: AJINOMOTO CO., INC.

The present invention provides a coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock comprising: a core containing a polysaccharide having a property of aggregating gram-negative bacteria; and a core coating agent. 1. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock comprising:a core containing a polysaccharide having a property of aggregating gram-negative bacteria; anda core coating agent.2. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , whereinthe polysaccharide is a polysaccharide containing, as a constituent sugar, at least one selected from the group consisting of mannose (Man), glucose (Glc), galactose (Gal), glucuronic acid (GlcA), mannuronic acid, and guluronic acid.3. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , whereinthe polysaccharide is at least one selected from the group consisting of pullulan, xanthan gum, guar gum, chitosan, carrageenan, arabic gum, pectin, carboxymethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, dextran, chondroitin, tara gum, locust bean gum, alginates (sodium salts, potassium salts, calcium salts, or ammonium salts), alginic acid esters, and mixtures thereof.4. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , wherein{'i': 'Xanthomonas campestris, Aureobasidium pullulans, Lipomyces starkeyi', 'the polysaccharide is a culture product of , or brown algae (Phaeophyta).'}5. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , whereinthe coating agent contains ...

Подробнее
Номер записи: 76
04-01-2018 дата публикации

ENHANCED MILK PRODUCTION EFFIENCIENCY IN DAIRY COWS

Номер: US20180000119A1
Автор: NESTOR Karl, Weiss William P.
Принадлежит:

A method of enhancing milk production efficiency in dairy cattle that comprises feeding the dairy cattle with a feed ration comprising a corn silage made from a brown midrib/floury-2 corn hybrid. Upon being fed to dairy cows, a feed ration comprising brown midrib/floury-2 corn silage provides at least about 4% higher in the amount of milk produced per unit of the feed intake, compared to a feed ration comprising non-brown midrib corn silage. 1. A method of enhancing milk production efficiency in dairy cattle , the method comprising:preparing a feed ration comprising a corn silage made from a brown midrib/floury-2 corn hybrid; andfeeding the dairy cattle with the feed ration to provide an increased amount of milk produced per one unit of the feed ration consumed by the dairy cattle.2. The method of claim 1 , wherein the amount of milk produced per one unit of the feed ration consumed is at least about 4% higher for the feed ration comprising the brown midrib/floury-2 corn hybrid compared to a feed ration comprising brown midrib corn hybrid without a floury-2 genotype.3. The method of claim 1 , wherein the brown midrib corn hybrid is a bm3/fl2 corn hybrid.4. The method of claim 1 , wherein the feed ration comprises the corn silage in an amount from about 40% to about 60% on dry matter basis.5. The method of claim 1 , wherein the feed ration comprises from about 40% to about 60% of the corn silage claim 1 , from about 5% to about 15% of alfalfa silage claim 1 , and from about 5% to about 15% of ground corn gain based on dry matter basis.6. The method of claim 5 , wherein the feed ration further comprises at least one ingredient selected from the group consisting of soybean meal claim 5 , soyhulls claim 5 , dried distillers gains with solubles claim 5 , animal or vegetable fat claim 5 , mineral salt claim 5 , sodium bicarbonate claim 5 , limestone claim 5 , dynamite claim 5 , dicalcium phosphate claim 5 , trace nutrient premix claim 5 , and combinations thereof.7. The ...

Подробнее
Номер записи: 77
04-01-2018 дата публикации

BEETLE POWDER

Номер: US20180000121A1
Автор: ARMENJON Benjamin, Berezina Nathalie, Hubert Antoine, Laurent Sophie, Sanchez Lorena, Socolsky Cecilia
Принадлежит: YNSECT

The present invention relates to a beetle powder containing at least 67% by weight protein and at least 5% by weight chitin, the weight percentages relating to the total weight of the beetle powder. The invention is also directed to a method for preparing the beetle powder and to the uses thereof, in particular in human or animal nutrition. 1. Beetle powder comprising at least 67% by weight proteins and at least 5% by weight chitin , the percentages by weight being given relative to the total weight of beetle powder.2. Beetle powder according to claim 1 , comprising ash in a content less than or equal to 4% by weight relative to the total weight of beetle powder.3. Beetle powder according to or claim 1 , comprising fat in a content comprised between 5 and 20% by weight relative to the total weight of beetle powder.4. Beetle powder according to any one of to claim 1 , the proteins of which exhibit a digestibility greater than or equal to 85%.5. Beetle powder according to any one of to claim 1 , the residual moisture content of which is comprised between 2 and 15%.6. Beetle powder according to any one of to claim 1 , comprising between 40 and 60% by weight soluble proteins relative to the total weight of proteins claim 1 , in which at least 50% of the soluble proteins have a size less than or equal to 12 claim 1 ,400 g/mol.7. Method for the preparation of a beetle powder according to any one of to claim 1 , comprising the following steps:i) killing the beetles,ii) pressing the beetles in order to obtain a press cake, andiii) grinding the press cake.8. Method according to claim 7 , also comprising a step of drying the press cake.12. Use of the beetle powder according to any one of to claim 7 , in human or animal nutrition.13. Use according to claim 12 , in which the beetle powder is used to replace protein flour. The present invention relates to an insect powder. It also relates to a method for the preparation of this powder and use thereof in human or animal nutrition ...

Подробнее
Номер записи: 78
04-01-2018 дата публикации

MICRO-ENCAPSULATED AQUACULTURE FEED

Номер: US20180000122A1
Автор: Kawakami Yutaka, Nagata Ryoichi
Принадлежит:

To provide a feed that does not pollute rearing water, improves the immunity activity of is capable of directly feeding eel and is capable of effectively inducing the growth of said larvae into glass eels. This micro-encapsulated aquaculture feed includes: an oil phase having an oil-soluble nutrient component; a water phase which is present inside the oil phase and which includes a water-soluble nutrient component; and a film which includes the oil phase and the water phase The water-soluble nutrient component includes at least one hydrolysate from among hydrolysates of amino acids, oligopeptides, and proteins. 1. Microencapsulated feed for aquaculture , comprising:{'b': '11', 'an oil phase () having an oil-soluble nutrient component;'}{'b': 13', '11, 'an aqueous phase () that is present in the oil phase () and contains a water-soluble nutrient component; and'}{'b': 15', '11', '13, 'a coating () containing the oil phase () and the aqueous phase (), wherein'}the water-soluble nutrient component contains any one or more of amino acids, oligopeptides, and protein hydrolysates.2. The feed for aquaculture according to claim 1 , wherein the water-soluble nutrient component further comprises saccharides selected from any one or more of monosaccharides claim 1 , oligosaccharides claim 1 , and polysaccharides.3leptocephalus larvaeleptocephalus larvae. The feed for aquaculture according to claim 1 , which is feed for of eels claim 1 , that is used for growing of eels up to glass eels.4. The feed for aquaculture according to claim 1 , whereinthe water-soluble nutrient component comprises a protein hydrolysate, andthe protein hydrolysate is obtained by hydrolyzing a protein source containing either or both of a vegetable protein and an animal protein, using a proteolytic enzyme, a hydrochloric acid, or hot water.5. The feed for aquaculture according to claim 1 , whereinthe water-soluble nutrient component comprises a protein hydrolysate, and the protein hydrolysate contains any ...

Подробнее
Номер записи: 79
04-01-2018 дата публикации

PET FOOD FEEDING SYSTEM

Номер: US20180000123A1
Автор: Duclos Laura, MITSUHASHI Yuka
Принадлежит: MARS, INCORPORATED

Compositions and methods are disclosed for providing a pet food feeding system or packaged product containing multiple formulations meeting a number of parameters in order to offer diversified ingredients and varied flavors to a pet with minimized digestive stress due to dietary changes. 1. A pet food feeding system , comprising:a first formulation having a first recipe; anda second formulation having a second recipe;wherein the first recipe is different than the second recipe, andwherein the first formulation and the second formulation each include between about 25 wt % and about 70 wt % protein supplying ingredients, between about 30 wt % and about 70 wt % carbohydrate supplying ingredients, between about 1.5 wt % and about 12 wt % fats and oils, between about 4 wt % and about 12 wt % total dietary fiber, and between about 1 wt % and 2.5 wt % total fermentable fiber.2. The pet food feeding system of claim 1 , wherein the first formulation includes at least 40 wt % of unique ingredients when compared with the second formulation.3. The pet food feeding system of claim 1 , wherein the first formulation and the second formulation further comprise up to about 6 wt % of additives.4. The pet food feeding system of claim 1 , wherein the first formulation and the second formulation comprise level of starch gelatinization of at least 83%.5. The pet food feeding system of claim 1 , wherein the first formulation includes a first caloric density and the second formulation includes a second caloric density claim 1 , and wherein the first caloric density has a value that is within 5% of a value of the second caloric density.67-. (canceled)8. The pet food feeding system of claim 1 , wherein:the first formulation is comprised of kibbles having a first shape,the second formulation is comprised of kibbles having a second shape, andthe first shape is different than the second shape.914-. (canceled)15. The pet food feeding system of claim 1 , wherein:the first formulation includes a ...

Подробнее
Номер записи: 80
04-01-2018 дата публикации

POULTRY FEED WITH COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES

Номер: US20180000124A1
Автор: CHEN Shuen Ei, CHUNG Thau Kiong
Принадлежит:

This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in poultry which have been subject to overfeeding. Feeds containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided. 1. A basal poultry feed additive composition comprising a combination of 25-Hydroxyvitamin D (25-OH D) , Vitamin C , Vitamin E and canthaxathin.2. A combination according to further comprising at least one bio-active ingredient selected from the group consisting of Vitamin D claim 1 , Vitamin B2 claim 1 , Vitamin B6 claim 1 , Niacin claim 1 , Pantothenic Acid claim 1 , Folic Acid claim 1 , Biotin claim 1 , Zinc claim 1 , Copper claim 1 , Manganese claim 1 , and Selenium.3. A combination according to wherein the amount of Vitamin E or Vitamin C to Canthaxanthin may range from 40:1 to 1:1; preferably from 20:1 to 1:1; and more preferably from 10:1 to 1:14. A feed or premix comprising a combination according to .5. A feed claim 1 , or premix according to which is suitable for poultry.6. A combination claim 1 , feed claim 1 , or premix according to wherein the 25-hydroxy vitamin D is 25-hydroxy vitamin D3 (25-OH D3).7. A feed or according to wherein:the amount of 25-OH D3 is from 15-200μg/kgthe amount of Vitamin E is from 40-400 mg/kgthe amount of ascorbic acid is from 40-400 mg/kg; andthe amount of canthaxanthin is from 1-15 mg/kg8. A feed according to wherein:the amount of 25-OH D3 is from 80-150 μg/kg;the amount of Vitamin E is from 30-300 mg/kg;the amount of ascorbic acid is from 80-300 mg/kg; andthe amount of canthaxanthin is from 1-15 mg/kg.9. A feed according to comprising:25-OH D3: 35-150μg/kg;Vitamin E: 80-300 mg/kg;Canthaxanthin: 3-12 mg/kg; andAscorbic acid: 100-300 mg/kg.10. A feed according to comprising:25-OH D3: 35 μg/kgVitamin E: 80 mg/kgCanthaxanthin: 3 mg/kg; ...

Подробнее
Номер записи: 81
04-01-2018 дата публикации

NOVEL LACTOCOCCUS GARVIEAE BACTERIOPHAGE LAC-GAP-1 AND USE THEREOF IN SUPPRESSING PROLIFERATION OF LACTOCOCCUS GARVIEAE BACTERIA

Номер: US20180000125A1
Автор: Hwang Soon Hye, Jun Soo Youn, Kang Sang Hyeon, Kwon An Sung, Yoon Seong Jun
Принадлежит:

The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient. 1. A Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill Lactococcus garvieae cells specifically , which has the genome represented by the nucleotide sequence of SEQ. ID. NO: 1.2. A composition for preventing and treating the infections of Lactococcus garvieae claim 1 , which comprises the bacteriophage Lac-GAP-1 of as an active ingredient.3. The composition for preventing and treating the infections of Lactococcus garvieae according to claim 2 , wherein said composition is used to prepare an immersion agent or a feed additive.4. A method for preventing or treating the infections of Lactococcus garvieae claim 2 , which comprises a step of administering to a subject the composition of comprising the bacteriophage Lac-GAP-1 as an active ingredient.5. The method for preventing or treating the infections of Lactococcus garvieae according to claim 4 , wherein said composition is administered to a subject in the form of an immersion agent or a feed additive. The present invention relates to a bacteriophage isolated from the nature that infects and kills Lactococcus garvieae cells, and a method for preventing and treating the infections of Lactococcus garvieae using a composition comprising the bacteriophage as an active ingredient. More particularly, the present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill Lactococcus garvieae cells specifically, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12686BP), and a method for ...

Подробнее
Номер записи: 82
04-01-2018 дата публикации

SYSTEM AND METHOD FOR PREPARING MICRO-INGREDIENT FEED ADDITIVES TO ANIMAL FEED RATIONS

Номер: US20180000127A1
Автор: Freeman Steve, White Joshua A.
Принадлежит:

A method and system are provided for preparing micro-ingredient feed additives for use in designated feed rations. A micro-ingredient system of the invention includes a plurality of bins that store designated micro-ingredients therein. A master controller of the delivery system provides signals to control system components based on programmed commands corresponding to micro-ingredient batches to be prepared. Slide gate mechanisms are used to prevent loss of micro-ingredients delivered to a receiving receptacle of the system. During delivery of the micro-ingredients to the receptacle and during processing, the micro-ingredients can become airborne and subsequently lost. The slide gate mechanisms also provide controlled access to the receiving receptacle to prevent system errors such as contamination of ingredients in the receptacle, or improper batching of a prescribed micro-ingredient mixture to be delivered to a designated feed ration. 1. A method for preparing micro-ingredients to be used in designated feed rations , said method comprising: '(i) at least one bin for holding a micro-ingredient therein, said bin having an opening for receiving the micro-ingredient; (ii) a dispensing device communicating with the at least one bin for dispensing the micro-ingredient from the at least one bin; (iii) a receiving receptacle for receiving the micro-ingredient dispensed; (iv) a slide gate mechanism mounted to the receiving receptacle, the slide gate mechanism having a slidable gate; (v) a controller communicating with said dispensing device and said slide gate mechanism, said controller including a micro-processor, computer coded instructions determining operation of the system, and an interface for sending output control signals to and receiving input signals from said slide gate mechanism; and', '(a) providing(b) operating said slide gate mechanism based on commands from said computer coded instructions resulting in the output control signals sent to said slide gate ...

Подробнее
Номер записи: 83
07-01-2021 дата публикации

EDIBLE FIBER

Номер: US20210000155A1
Автор: Engmann Jan, Janecek Emma Rose, Michaud Veronique, Qu Yunpeng, Sordo Federica, Sorin Fabien, Stellacci Francesco, Wooster Timothy James
Принадлежит:

The invention provides an edible fiber comprising a biopolymer and a plasticiser; wherein the weight ratio of biopolymer to plasticiser is about 1:0.25 to about 1:3; and wherein the fiber has a diameter of about 0.5 μm to about 1 mm. 1. An edible fiber comprising a biopolymer and a plasticiser:wherein the weight ratio of biopolymer to plasticiser is about 1:0.25 to about 1:3; andwherein the fiber has a diameter of about 0.5 μm to about 1 mm.2. The edible fiber of claim 1 , wherein the fiber has an aspect ratio of at least about 10.3. The edible fiber of claim 1 , wherein the biopolymer comprises a protein and/or a polysaccharide.4. The edible fiber of claim 1 , wherein the biopolymer is selected from the group consisting of gelatin claim 1 , casein claim 1 , egg white albumin claim 1 , soy protein claim 1 , whey protein claim 1 , wheat gluten claim 1 , pea protein claim 1 , sorghum kafirin claim 1 , and millet prolamin.5. The edible fiber of claim 1 , wherein the biopolymer is selected from the group consisting of pectin claim 1 , alginate claim 1 , and agar.6. The edible fiber of claim 1 , wherein the plasticiser comprises a polyol.7. The edible fiber of claim 6 , wherein the polyol is selected from the group consisting of glycerol claim 6 , sorbitol claim 6 , glucose claim 6 , sucrose claim 6 , maltitol claim 6 , xylitol claim 6 , erythritol claim 6 , and isomalt.8. The edible fiber of claim 1 , wherein the fiber comprises at least one hollow channel.9. A process for producing an edible fiber claim 1 , the process comprising the steps of:(a) combining a biopolymer and a plasticiser in a weight ratio of biopolymer to plasticiser of about 1:0.25 to about 1:3 to produce a preform; and(b) subjecting the preform to thermal drawing to produce an edible fiber.10. (canceled)11. The process of claim 9 , wherein thermal drawing is carried out at a drawing temperature of about 30° C. to about 300° C.1213-. (canceled)14. A food claim 9 , cosmetic claim 9 , pharmaceutical ...

Подробнее
Номер записи: 84
04-01-2018 дата публикации

Product and Method for Providing Enrichment and Facilitating Expression of Natural Behaviors in Pigs

Номер: US20180000129A1
Автор: Callaghan Matthew John, Van Barneveld Robert John
Принадлежит:

The present invention relates to a formulation that can be utilised to facilitate expression of natural behaviour in pigs, and in particular sows and weaners and a method which utilises the formulation for the same. 1. A composition comprising of molasses , insoluble fibre , triglyceride oil and salt.2. A composition according to which further comprises a setting agent or combination thereof.3. A composition according to or which is presented as a solid or semi-solid composition.4. A composition according to which is presented as a solid form.5. A composition according to which is presented as a block composition.6. A composition according to any one of to wherein the composition comprises:a) about 40% to about 70% w/w molasses;b) about 10% to about 30% w/w insoluble fibre;c) about 1% to about 5% w/w triglyceride oil; andd) about 2% to about 10% w/w salt.7. A composition according to wherein the composition comprises:a) about 40% to about 70% w/w molasses;b) about 10% to about 30% w/w insoluble fibre selected from maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean or soybean meal, sugar beet or beet pulp, sugarcane, tobacco, barley and oilseed rape;c) about 1% to about 5% w/w triglyceride oil selected from aceituno oil, almond oil, araehis oil, babassu oil, blackcurrant seed oil, borage oil, buffalo ground oil, candlenut oil, canola oil, castor oil, coconut oil, coffee seed oil, corn oil, cottonseed oil, crambe oil, evening primrose oil, grapeseed oil, groundnut oil, hemp seed oil, kapok seed oil, linseed oil, mustard seed oil, olive oil, palm oil, palm kernel oil, peanut oil, poppy seed oil, rapeseed oil, rice bran oil, safflower oil, sesame oil, shark liver oil, shea nut oil, soybean oil, sunflower oil, tea seed oil, tobacco seed oil, vermonia oil, vegetable oil and wheat germ oil; andd) about 2% to about 10% w/w of salt selected from sodium chloride and sodium nitrite.8. A composition according to any one of to where in ...

Подробнее
Номер записи: 85
04-01-2018 дата публикации

FEED INGREDIENTS COMPRISING LYSED MICROBIAL CELLS

Номер: US20180000130A1
Автор: Lu Wenhua, Piechocki John, Rakitsky Walter
Принадлежит:

The present disclosure relate to feed ingredients and formulated feed, methods for their manufacture, and uses thereof in nutritional applications such as in aquaculture, terrestrial animal feed, and human nutrition. The feed ingredient compositions comprise lysed microbial cells with a small aspect ratio and triglyceride oil. 1. A feed ingredient composition comprising a dispersion of lysed microalgal cells in triglyceride oil , wherein:a. 5-90% by weight of the feed ingredient composition is lysed microalgal cells, andb. 10-95% by weight of the feed ingredient composition is triglyceride oil, wherein the triglyceride oil comprises oil from the lysed cells and oil from another organism.2. The composition of claim 1 , wherein the triglyceride oil has a fatty acid profile of 10-50% docosahexaenoic acid (DHA) by weight of fatty acids.36.-. (canceled)7. The composition of claim 1 , wherein the lysed cells have an aspect ratio of less than 1:1.89.-. (canceled)10. The composition of claim 7 , wherein the oil from the another organism is oil from a fish claim 7 , plant claim 7 , oleaginous microbe claim 7 , animal claim 7 , or combinations thereof.1112.-. (canceled)13. The composition of claim 1 , wherein the microalgal cells are from the family Thraustochytriacae.14Crypthecodinium, Thraustochytrium, AurantiochytriumSchizochytrium.. The composition of claim 13 , wherein the microbial cells are from the genus selected from the group consisting of claim 13 , and15. The composition of claim 1 , wherein the microalgal cell is adapted to grow in low chloride conditions.1621.-. (canceled)22. A method for preparing a composition of comprising:a) blending microbial cells and the oil from another organism to form a blend; andb) lysing the microbial cells in the blend to form the composition as a dispersion.23. A method for preparing a formulated feed claim 1 , the method comprising the steps of contacting the feed ingredient composition of with an edible food.2443.-. (canceled)44. ...

Подробнее
Номер записи: 86
07-01-2016 дата публикации

Methods of Using C-Met Modulators

Номер: US20160000772A1
Автор: Aftab Dana T., Holland Jaymes, Mueller Thomas, Weitzman Aaron
Принадлежит:

Methods of treating cancer by administering a compound of Formula I, 115-. (canceled)18. The method according to claim 16 , wherein the compound or a pharmaceutically acceptable salt thereof claim 16 , further comprises a pharmaceutically acceptable carrier claim 16 , excipient claim 16 , or diluent.19. The method according to claim 18 , wherein the concurrent phase is 6-7 weeks in duration claim 18 , and the rest phase is about 4 weeks in duration; and the maintenance phase is of a duration sufficient slow down the cancer growth. This application is a continuation application of U.S. Ser. No. 13/389,266, filed Feb. 7, 2012, which claims priority under 35 U.S.C. §371 to Patent Cooperation Treaty application PCT/US2010/044749, filed Aug. 6, 2010, which claims the benefit of U.S. Provisional application No. 61/232,382, filed Aug. 7, 2009, the entire contents of which are incorporated herein by reference.This invention relates to methods of using c-Met modulators, and specifically c-Met modulators in combination with other anti-cancer agents and/or radiation, which can be useful for the modulation of various cellular activities and for the treatment of various diseases as described in the specification.Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms. One mechanism that can be exploited in cancer treatment is the modulation of protein kinase activity because signal transduction through protein kinase activation is responsible for many of the characteristics of tumor cells. Protein kinase signal transduction is of particular relevance in, for example, thyroid, gastric, head and neck, lung, breast, prostate, and colorectal cancers, as well as in the growth and proliferation of brain tumor cells.Protein kinases can be categorized as receptor type or non-receptor type. Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse ...

Подробнее
Номер записи: 87
07-01-2016 дата публикации

PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS

Номер: US20160000799A1
Автор: Damle Shantanu Yeshwant, Gandhi Rajesh, Nekkanti Vijay Kumar, Padhi Bijay Kumar, Raghuvanshi Rajeev Singh
Принадлежит:

The present application discloses a pharmaceutical composition comprising a class of cholesteryl ester transfer protein (CETP) inhibitors with improved oral bioavailability. The application further discloses compositions comprising a class of CETP inhibitor and at least one surfactant in the form of a solution, suspension, emulsion or a pre-concentrate. 2. (canceled)6. The composition according to claim 1 , wherein the surfactant is hydrophilic claim 1 , hydrophobic or mixtures thereof.7. The composition according to claim 1 , wherein the surfactant comprises from about 1% to about 90% weight of the composition.8. The composition according to claim 6 , wherein the hydrophilic surfactant is anionic claim 6 , cationic claim 6 , zwitterionic or non-ionic.9. The composition according to claim 8 , wherein the anionic surfactant is selected from group consisting of fatty acid salts claim 8 , bile salts claim 8 , phospholipids claim 8 , phosphoric acid esters claim 8 , carboxylates claim 8 , acyl lactylates claim 8 , alginate salts claim 8 , sulfates and sulfonates claim 8 , cationic surfactants and combinations thereof.1017-. (canceled)18. The composition according to claim 8 , wherein the cationic surfactant is selected from group comprising lauroyl carnitine claim 8 , palmitoyl carnitine claim 8 , myristoyl carnitine claim 8 , hexadecyl triammonium bromide claim 8 , decyl trimethyl ammonium bromide claim 8 , cetyl trimethyl ammonium bromide claim 8 , dodecyl ammonium chloride claim 8 , alkyl benzyldimethylammonium salts claim 8 , diisobutyl phenoxyethoxydimethyl benzylammonium salts claim 8 , alkylpyridinium salts claim 8 , betaines (trialkylglycine): lauryl betaine (N-lauryl claim 8 , N claim 8 ,N-dimethylglycine) claim 8 , ethoxylated amines: polyoxyethylene-15 coconut amine and combinations thereof.19. The composition according to claim 8 , wherein the non-ionic surfactant is selected from group comprising polyethoxylated fatty Acids claim 8 , PEG fatty acid diesters ...

Подробнее
Номер записи: 88
03-01-2019 дата публикации

ANIMAL FEED BOLUS AND METHODS FOR MANUFACTURING THE SAME

Номер: US20190000758A1
Автор: BEGUIN Jean Marie, DAGORNE Rene-Pol
Принадлежит: CAN TECHNOLOGIES, INC.

The present invention relates to an animal feed bolus having two or more sections, wherein each section has a different composition. The different sections of the bolus are formulated to have different release times and/or to provide compositions with different nutritional purposes. Also described herein are methods for manufacturing such boluses, and methods for feeding an animal using such boluses. 1. An animal feed bolus , comprising:a first section, anda second section connected to the first section,wherein the first section has a different composition and release rate than the second section.2. (canceled)3. The bolus of claim 1 , wherein the release rate of the first section is less than one day.4. The bolus of claim 1 , wherein the release rate of the first section is less than 12 hours.5. The bolus of claim 1 , wherein the release rate of the first section is less than 6 hours.6. The bolus of claim 1 , wherein the release rate of the first section is less than 1 hour.7. The bolus of claim 2 , wherein the release rate of the second section is greater than 2 days.8. The bolus of claim 2 , wherein the release rate of the second section is greater than 1 week.9. The bolus of claim 2 , wherein the release rate of the second section is greater than 15 days.10. (canceled)11. The bolus of claim 1 , wherein the first section comprises about 50 wt % of the bolus.12. The bolus of claim 1 , wherein the first section comprises about 40 wt % of the bolus.13. The bolus of claim 1 , wherein the first section comprises less than about 30 wt % of the bolus.14. The bolus of claim 1 , wherein the first section comprises less than about 20 wt % of the bolus.15. The bolus of claim 1 , wherein the first section comprises less than about 10 wt % of the bolus.16. The bolus of claim 1 , wherein the first section comprises vitamin E.17. (canceled)18. The bolus of claim 1 , wherein the second section comprises a nutrient selected from the group consisting of zinc claim 1 , selenium ...

Подробнее
Номер записи: 89
04-01-2018 дата публикации

SUSPENSION COMPOSITIONS OF PHYSIOLOGICALLY ACTIVE PHENOLIC COMPOUNDS & METHODS OF MAKING AND USING THE SAME

Номер: US20180000773A1
Автор: Dykstra John C., Egberg David C., Kaytor Michael D.
Принадлежит: Humanetics Corporation

The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid. 149-. (canceled)50. A treatment regimen for a subject , comprising: an edible lipid; and', 'an active material suspended within the edible lipid forming a nanoparticulate suspension, wherein the active material comprises a physiologically active phenolic compound and exhibits a particle size distribution characterized by a D (0.50) of 0.5 μm or less., 'administration of a therapeutically effective amount of a composition to a subject during an administration period, the composition comprising51. The treatment regimen of claim 50 , wherein the composition is administered daily to the subject throughout the administration period.52. The treatment regimen of claim 50 , wherein the total daily dose of the composition administered to the subject during the administration period is selected from about 50 mg/day to about 10 claim 50 ,000 mg/day claim 50 , about 50 mg/day to about 9 claim 50 ,000 mg/day claim 50 , about 50 mg/day to about 8 claim 50 ,000 mg/ day claim 50 , about 50 mg/day to about 2 claim 50 ,000 mg/day claim 50 , about 100 mg/day to about 9 claim 50 ,000 mg/day claim 50 , about 100 mg/day to about 5 claim 50 ,000 mg/day claim 50 , about 100 mg/day to about 4 claim 50 ,000 mg/ day claim 50 , about 100 mg/day to about 2 claim 50 ,000 mg/day claim 50 , and about 100 mg/day to about 1 claim 50 ,000 mg/day.53. The treatment regimen of claim 52 , wherein the total daily dose is about 1 claim 52 ,000 mg/day.54. The treatment regimen of claim 50 , wherein the composition is administered to the subject according to a dosing schedule selected from at least one of a single dose claim 50 , a regular daily ...

Подробнее
Номер записи: 90
02-01-2020 дата публикации

Composition for controlled release of physiologically active substances and process for its preparation

Номер: US20200000733A1
Автор: Arnaldo VALENTINI, Devis UNGHERI, Enrico GASPARI, Flavio FARNEDI
Принадлежит: Bioscreen Technologies SRL

The present invention relates to a rumen-resistant composition in the form of microgranules, a process for its production and a feedstuff containing such composition.

Подробнее
Номер записи: 91
05-01-2017 дата публикации

ANTIMICROBIAL COMPOSITIONS AND USES THEREOF

Номер: US20170000755A1
Автор: Arhancet Graciela B., Grega Mariya, Kuttappan Vivek, Lichtenstein Drew L., Long Scott, Mahoney Matthew, Monestel Jeffery Escobar, Vazquez-Anon Mercedes
Принадлежит:

Antimicrobial compositions comprising sulfur- or selenium-containing, fatty-acylated alpha-hydroxy acid compounds and methods of using said compounds or compositions to inhibit microbial growth. 2. The antimicrobial composition of claim 1 , wherein Ris alkyl claim 1 , substituted alkyl claim 1 , alkenyl claim 1 , substituted alkenyl claim 1 , aryl or substituted aryl claim 1 , and Ris alkyl claim 1 , substituted alkyl claim 1 , alkenyl claim 1 , substituted alkenyl claim 1 , aryl claim 1 , or substituted aryl.3. The antimicrobial composition of claim 2 , wherein Ris C-Calkyl claim 2 , and Ris C-Calkyl or C-Calkenyl claim 2 , k is from 1 to 10 claim 2 , and n is from 1 to 3.4. The antimicrobial composition of claim 3 , wherein Ris methyl claim 3 , Ris C-Calkyl claim 3 , Y is hydrogen or an alkali metal claim 3 , Z is sulfur claim 3 , and n is 2.5. The antimicrobial composition of claim 1 , wherein the essential oil is chosen from cinnamon claim 1 , lavender claim 1 , oregano claim 1 , rosemary claim 1 , or thyme; the metal chelate is an amino acid chelate or an organic acid chelate of calcium claim 1 , chromium claim 1 , copper claim 1 , iron claim 1 , magnesium claim 1 , manganese claim 1 , selenium claim 1 , or zinc; the mineral is a salt claim 1 , chelate claim 1 , or complex of calcium claim 1 , chromium claim 1 , copper claim 1 , iodine claim 1 , iron claim 1 , magnesium claim 1 , manganese claim 1 , molybdenum claim 1 , phosphorus claim 1 , potassium claim 1 , selenium claim 1 , or zinc; the enzyme is chosen from phytases claim 1 , proteases claim 1 , or carbohydrases; the ionophore is chosen from bambermycin claim 1 , decoquiate claim 1 , declazuril claim 1 , lasalocid claim 1 , maduramicin claim 1 , monensin claim 1 , narasin claim 1 , nicarazin claim 1 , nystatin claim 1 , robenedine claim 1 , salinomycin claim 1 , or semduramicin; the mycotoxin binder is chosen from charcoal claim 1 , activated carbon claim 1 , phyllosilicates claim 1 , tectosilicates claim ...

Подробнее
Номер записи: 92
07-01-2021 дата публикации

ANIMAL FEED ADDITIVE AND ANIMAL FEED

Номер: US20210000913A1
Автор: MAEKAWA Mayumi, Nakagawa Kazuki, UEHARA Akinori
Принадлежит: AJINOMOTO CO., INC.

The present invention provides a coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock comprising: a core containing a physiologically active substance having a property of strengthening a membrane of intestinal epithelial cells; and a core coating agent. 1. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock comprising:a core containing a physiologically active substance having a property of strengthening a membrane of intestinal epithelial cells; anda core coating agent.2. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , whereinthe physiologically active substance contains at least one selected from the group consisting of bacteriocins, polyphenols, amino acids or derivatives thereof, organic acids or derivatives thereof, HSP inducers, antioxidants, and polysaccharides.3. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , whereinthe physiologically active substance is at least one bacteriocin selected from the group consisting of nisin, subtilin, plantaricin, and gassericin.4. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , whereinthe physiologically active substance is contained in a culture of a microorganism which produces the substance.5. A coated-type feed additive composition for improving body weight gain of livestock or feed conversion ratio for livestock according to claim 1 , wherein{'i': Bacillus, Lactococcus, Lactobacillus, Leuconostoc', 'Pediococcus., 'the physiologically active substance is contained in a culture of at least one microorganism selected from the group consisting of , and'}6. A coated-type feed additive composition ...

Подробнее
Номер записи: 93
05-01-2017 дата публикации

FOOD SUPPLEMENTATION COMPOSITION CONTAINING ONE OR MORE VITAMIN D3 COMPOUNDS AND ONE OR MORE MAGNESIUM SALTS

Номер: US20170000805A1
Автор: ELLIOTT Robert, WEBER Gilbert
Принадлежит:

Use of one or more vitamin Dcompounds chosen from the group 1-α-hydroxy vitamin D, 25-hydroxy vitamin D, 1-α-, 25-dihydroxy vitamin D, in combination with one or more magnesium salts to prevent milk fever mammals. 110-. (canceled)11. A method of substantially ameliorating milk fever in an animal prior to calving comprising: from about 100 μg per kg to about 1000 μg per kilogram 25 hydroxy vitamin D3; and', 'one or more magnesium salts;, 'administering a dry food composition comprisingto said animal; a dry food; and', 'a premix comprising said 25 hydroxy vitamin D3., 'wherein the dry food composition comprises12. The method of wherein said premix is the sole source of 25 hydroxy vitamin D3 administered to said animal.13. The method according to claim 11 , wherein the magnesium salt is magnesium chloride and/or magnesium sulphate.14. The method according to claim 11 , wherein the animal is a dairy cow.15. The method according to claim 11 , wherein the administering starts one to four weeks prior to calving.16. The method according to claim 11 , wherein the administration starts approximately two weeks prior to calving.17. The method according to claim 11 , wherein the administering is daily.18. A method for substantially ameliorating milk fever in an animal claim 11 , said method comprising the step of administering to the animal prior to calving and in need of such treatment an amount of 1 mg to 10 mg of 25-hydroxy vitamin D3 and from 50 g to 150 g of magnesium chloride and/or magnesium sulphate per day wherein administering comprises the step of administering a dry food composition comprising:a dry food; anda premix comprising said 25 hydroxy vitamin D3.19. The method according to claim 18 , wherein said premix is the sole source of 25 hydroxy vitamin D3 administered to said animal.20. The method according to claim 18 , wherein the animal is a dairy cow.21. The method according to claim 18 , wherein the administering starts one to four weeks prior to calving.22. The ...

Подробнее
Номер записи: 94
05-01-2017 дата публикации

STABILIZING COMPOSITION FOR BIOLOGICAL MATERIALS

Номер: US20170000892A1
Автор: Carpenter Brian, Drewes Roger, Harel Moti, Jennings Kimberly, Raditsis Elizabeth, Rice Trisha, Scarbrough January, Tang Qiong
Принадлежит: Advanced Bionutrition Corporation

Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw. 1. A dry stabilizing composition , comprising a bioactive material , one or more disaccharides at 10-50% , one or more oligosaccharides at 10-80% , one or more polysaccharides at 0.1-10% , one or more hydrolyzed proteins at 0.5-40% , and one or more carboxylic acid salts , each percentage based on the total weight of the composition.2. The dry stabilizing composition of claim 1 , wherein the bioactive material comprises a cell claim 1 , a virus claim 1 , a bacterium claim 1 , a yeast claim 1 , a protein claim 1 , a hormone claim 1 , a vaccine claim 1 , a drug or a mixture thereof.3. The dry stabilizing composition of claim 2 , wherein the bacterium is a probiotic bacterium.4. The dry stabilizing composition of claim 2 , wherein the virus is an attenuated virus.5. The dry stabilizing composition of claim 1 , further comprising vitamin E.6. The dry stabilizing composition of claim 1 , wherein the one or more oligosaccharides comprise cyclodextrin.7. The dry stabilizing composition of claim 1 , wherein the one or more oligosaccharides comprise cyclodextrin and inulin.8. The dry stabilizing composition of claim 1 , wherein the one or more carboxylic acid salts ...

Подробнее
Номер записи: 95
04-01-2018 дата публикации

Method for Mixing of Particles

Номер: US20180001280A1
Автор: Bach Poul
Принадлежит: NOVOZYMES A/S

Continuous mixing in a static mixer possible can be used to add one kind of particles (such as an enzyme granular product) in a small amount to a larger amount of a different kind of particles (such as a powder stream of detergent powder), even if the powder characteristics are substantially different, with substantially no damage to the enzyme particles and with a high degree of homogeneity. 1. A method for mixing of at least two kinds of particles , wherein a first and a second stream of particles are mixed in a static mixer , and wherein the first and the second stream of particles have a weight ratio below 1:20.2. The method of wherein the ratio is below 1:50 claim 1 , particularly in the range from 1:1000 to 1:100 claim 1 , or from 1:500 to 1:125.3. The method of claim 1 , wherein the average particle size of the first stream of particles is in the range 100-2000 μm.4. The method of claim 1 , wherein the average particle size of the first stream of particles is in the range 300-1200 μm.5. The method of claim 1 , wherein the coefficient of variation of the amount of particles from the first stream claim 1 , in the resulting mixture of the first and second stream of particles claim 1 , is less than 40%.6. The method of claim 5 , wherein the coefficient of variation is measured using at least 9 samples and a sample size of at least 5 g.7. The method of claim 1 , wherein the first stream comprises enzyme particles.8. The method of claim 7 , wherein the enzyme particles comprise a protease claim 7 , an amylase claim 7 , a carbohydrase claim 7 , a lipase claim 7 , a cellulase claim 7 , an oxidoreductase claim 7 , a mannanase or a pectate lyase or a phosphatase claim 7 , or a deoxyribonuclease.9. The method of claim 7 , wherein the resulting mixture of the enzyme particles and the second stream of particles has an amount of free enzyme dust below 20 parts per billion.10. The method of claim 1 , wherein the second stream comprises detergent granules or detergent powder ...

Подробнее
Номер записи: 96
07-01-2016 дата публикации

Method of increasing lipid accumulation in metschnikowia pulcherrima cells

Номер: US20160002679A1
Автор: Christopher CHUCK, Fabio SANTOMAURO, Roderick Scott
Принадлежит: University of Bath

The invention relates to a method of increasing lipid accumulation in Metschnikowia pulcherrima ( Candida pulcherrima ) cells. In particular, the invention relates to a method of obtaining oil from yeast pulcherimma cells. The invention further relates to an oil and the use of pulcherimma cells for production of oleaginous biomass.

Подробнее
Номер записи: 97
07-01-2021 дата публикации

OLIGOSACCHARIDE COMPOSITIONS AND METHODS FOR PRODUCING THEREOF

Номер: US20210002387A1
Автор: "OCONNOR Andrew", CHURCHMAN Devin, GEREMIA John M., HAN Scott, LANDRY Alicia, MURPHY Anastasia V., PANOS Stephen, SEIGAL Benjamin A., SHERRY Kyle
Принадлежит:

Described herein are methods for the production of oligosaccharides, including functionalized oligosaccharides, from one or more sugars, such as one or more monosaccharides, using polymeric and solid-supported catalysts containing acidic and ionic groups. Also provided are the oligosaccharide compositions, including functionalized oligosaccharide compositions, obtained using the methods. 126-. (canceled)27. An oligosaccharide composition prepared according to a method comprising condensation polymerization of one or more sugars to produce the oligosaccharide composition; wherein:', 'each of the monosaccharide monomers is selected from the group consisting of C5 monosaccharides and C6 monosaccharides; at least 15% of the oligosaccharide composition has a degree of polymerization (DP) of at least four; 5 to 25% of the oligosaccharide composition has a degree of polymerization (DP) of three; and 5 to 30% of the oligosaccharide composition has a degree of polymerization (DP) of two;', 'the mean DP of the oligosaccharide composition is 10-15; and, 'monosaccharide monomers connected by glycosidic bonds;'}, 'the oligosaccharide composition comprisingat least a portion of the glycosidic bonds in the oligosaccharide composition comprises β-1,2 bonds and α-1,3 bonds.28. The oligosaccharide composition of claim 27 , wherein the monosaccharide monomers are glucose claim 27 , galactose claim 27 , xylose claim 27 , arabinose claim 27 , fructose claim 27 , mannose claim 27 , ribose claim 27 , allose claim 27 , fucose claim 27 , or rhamnose.29. The oligosaccharide composition of claim 27 , wherein the monosaccharide monomers are connected by glycosidic bonds to form oligomer backbones claim 27 , and wherein the oligomer backbones are optionally substituted with one or more pendant functional groups claim 27 , wherein the pendant functional groups are carboxylic acids claim 27 , sugar alcohols claim 27 , amino acids claim 27 , amino sugars claim 27 , alcohols claim 27 , sulfate ...

Подробнее
Номер записи: 98
04-01-2018 дата публикации

COMPOSITIONS AND METHODS THEREOF FOR DOWN-REGULATION OF GENES FOLLOWING ORAL DELIVERY OF AN RNAI MOLECULE BIOENCAPSULATED WITHIN PLANT CELLS

Номер: US20180002716A1
Автор: Daniell Henry
Принадлежит:

Compositions and methods for down-regulating genes through oral administration of RNAi molecule encapsulated in plant cells are provided. 1. A recombinant plant plastid or viral expression vector which comprises , as operably linked components in the 5′ to 3′ direction of translation , a promoter operable in said plant , a heterologous polynucleotide sequence coding for at least one RNAi molecule selected from the group comprising dsRNA , siRNA , shRNA , and miRNA and a transcription terminator functional in said plant , said vector optionally encoding a nucleic acid encoding a selectable marker.2. The vector of claim 1 , suitable for stable or transient plant transformation.3. The vector of claim 1 , wherein said RNAi molecule has been optimized and comprises one or more step loop structures claim 1 , high AT content claim 1 , and a 2 nucleotide TT 3′ overhang claim 1 , said RNAi molecule lacking complementarity to 3′UTRs in endogenous plant genes claim 1 , said optimized RNAi molecule exhibiting reduced off target effects relative to RNAi molecules which has not been optimized.4. The vector of claim 1 , comprising a selectable marker which is an antibiotic resistance marker.5. The vector of claim 1 , comprising a heterologous polynucleotide sequence coding for at least one RNAi molecule that down-regulates a P450 monooxygenase gene claim 1 , a Vac ATPase A gene claim 1 , and a chitin synthase B gene.6. The vector of claim 1 , comprising a heterologous polynucleotide sequence coding for an RNAi molecule that down-regulates the P450 monooxygenase gene.7. The vector of claim 1 , comprising a heterologous polynucleotide sequence coding for an RNAi molecule that down-regulates the Vac ATPase A gene.8. The vector of claim 1 , comprising a heterologous polynucleotide sequence coding an RNAi molecule that down-regulates the chitin synthase B gene.9. The vector of claim 1 , comprising a heterologous polynucleotide sequence coding for an RNAi molecule that down-regulates ...

Подробнее
Номер записи: 99
13-01-2022 дата публикации

APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE

Номер: US20220007684A1
Автор: Huang Huacheng, PENG Xianfeng
Принадлежит:

The present invention provides an acylated derivative of an amino acid for use in preparing an animal feed additive. The acylated derivative of the amino acid or a racemate, stereoisomer, a geometric isomer, a tautomer, a solvate, and a feed-acceptable salt thereof of the present invention has a structure represented by formula (I). 2. The acylated derivative according to claim 1 , wherein X is C-Calkylene.3. The acylated derivative according to claim 1 , wherein Ris RC(═O) or H; and Ris RC(═O).4. The acylated derivative according to claim 1 , wherein each of Rand Ris independently C-Calkyl claim 1 , wherein C-Calkyl is optionally substituted with 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 or 5 R; and{'sup': '3', 'sub': 2', '1', '1, 'Ris —OH, —NH, —CN, —SH or —X, wherein Xis selected from F, Cl, Br or I.'}5. The acylated derivative according to claim 1 , wherein each of Rand Ris independently C-Calkyl claim 1 , wherein C-Calkyl is optionally substituted with 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 or 5 R; and{'sup': '3', 'sub': 2', '1', '1, 'Ris —OH, —NH, —CN, —SH or —X, wherein Xis selected from F, Cl, Br or I.'}6. The acylated derivative according to claim 1 , wherein each of Rand Ris independently straight chain C-Calkyl.7. The acylated derivative according to claim 1 , wherein Ris RC(═O) or H; and Ris RC(═O).8. The acylated derivative according to claim 1 , wherein each of Rand Ris independently C-Caryl or —(C-Calkylene)-C-Caryl claim 1 , wherein each of C-Caryl and —(C-Calkylene)-C-Caryl is optionally substituted with 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , or 5 R;{'sup': '4', 'sub': 2', '2', '2', '1', '5', '1', '5', '1', '5', '2', '2, 'Ris —OH, —NH, —NO, —CN, —SH, —X, —C-Calkoxy, —C-Calkyl, or —C-Calkyl substituted with X, wherein Xis selected from F, Cl, Br or I.'}9. The acylated derivative according to claim 1 , wherein each of Rand Ris independently Caryl and —(C-Calkylene)-Caryl claim 1 , wherein each of Caryl and —(C-Calkylene)-Caryl is optionally ...

Подробнее
Номер записи: 100